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ABSTRACT 
Motivation: Signaling pathways control a large variety of cellular 
processes. However, currently, even within the same database 
signaling pathways are often curated at different levels of detail. This 
makes comparative and cross-talk analyses difficult. 
Results: We present SignaLink, a database containing 8 major 
signaling pathways from Caenorhabditis elegans, Drosophila 
melanogaster, and humans. Based on 170 review and ~800 
research articles, we have compiled pathways with semi-automatic 
searches and uniform, well-documented curation rules. We found 
that in humans any two of the 8 pathways can cross-talk. We 
quantified the possible tissue- and cancer-specific activity of cross-
talks and found pathway-specific expression profiles. In addition, we 
identified 327 proteins relevant for drug target discovery. 
Conclusions: We provide a novel resource for comparative and 
cross-talk analyses of signaling pathways. The identified multi-
pathway and tissue-specific cross-talks contribute to the 
understanding of the signaling complexity in health and disease and 
underscore its importance in network-based drug target selection. 
Availability: http://SignaLink.org 
1 INTRODUCTION  
Intracellular signaling, from the simplest cascades to the highly 
intertwined networks of protein kinases, contributes extensively to 
the diversity of developmental programs and adaptation responses 
in metazoans (Pires-daSilva and Sommer, 2003). In humans, 
defects in intracellular signaling can cause various diseases, e.g., 
cancer, neurodegeneration, or diabetes. Thus, understanding the 
structure, function, and evolution of signal transduction is an 
important task for both basic research and medicine. By now 
genetic studies have uncovered functionally separate, though 
interacting (cross-talking), pathways and the direction of 
information flow between pairs of signaling molecules in a number 
of species (Beyer et al., 2007). On the other hand, biochemical 
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experiments have allowed the detailed characterization of direct 
physical interactions involved in signaling (Xia et al., 2004). 
Integrating these data sets using uniform manual curation criteria 
can significantly contribute to a more precise assessment of their 
tissue- and cancer-specific utilization and the effects of drug 
treatments (Davidov et al., 2003). For example, inhibitors used for 
eliminating a signaling pathway in cancerous cells may in fact 
have the opposite effect. These drugs may suppress negative 
feedback loops and thereby, paradoxically, activate the targeted 
pathway (Sergina et al., 2007). 
Intracellular signaling was originally regarded as an assembly of 
distinct and almost linear cascades. Over the past decade, however, 
it has been realized that signaling pathways are highly structured 
and rich in cross-talks (where cross-talk is defined here as a 
directed physical interaction between pathways). Consequently, 
intracellular signaling is now viewed as a set of intertwined 
pathways forming a single signaling network (Papin et al., 2005). 
This paradigm shift calls for novel experimental, curation, and 
network modeling techniques (Bauer-Mehren et al., 2009).  
Currently, high-throughput (HTP) experiments are the major 
sources of known protein-protein interactions. However, so far in 
most HTP experiments extracellular, membrane-bound, and 
nuclear proteins have been underrepresented. These and other 
sampling biases strongly reduce their usability for identifying 
signaling interactions. Another limitation of HTP assays is that 
they produce undirected interactions even though in signaling 
directions are essential. Accordingly, several signaling pathway 
databases have been created recently by manually collecting the 
directed interactions from the literature (Bauer-Mehren et al., 
2009). 
Manually curated signaling pathway databases are often assembled 
without strictly defined and published standardized curation 
criteria (Lu et al., 2007). Therefore, even within the same database, 
e.g., in KEGG (Ogata et al., 1999), the level of detail of curation 
and the rules for setting pathway boundaries can vary among 
pathways. In addition, in several signaling resources the definition 
of signaling pathways has no evolutionary or biochemical 
background. In other cases, e.g., in Reactome and NetPath 
(Kandasamy et al., 2010; Joshi-Tope et al., 2005), curation criteria 
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are standardized, however, (i) pathways are usually handled as 
separate entities, (ii) cross-talks and multi-pathway proteins are 
underrepresented, and (iii) extracting signaling information from 
the databases are complicated and labor-intensive, see Discussion 
and Supplementary Data for details. Another limitation of several 
current signaling resources is that they neglect the importance of 
multi-pathway proteins, i.e., proteins functioning in more than one 
pathway (Komarova et al., 2005). In summary, the manual curation 
process needs to be uniform across all pathways and species to aid 
cross-talk analyses, tests of evolutionary hypotheses, dynamical 
modeling, setting up predictions, and drug target selection (Table 
1).  
We present SignaLink, a signaling resource compiled by applying 
uniform manual curation rules and data structures across 8 major, 
biochemically defined signaling pathways in 3 metazoans (Fig. 1). 
The curation method allowed a systematic comparison of pathway 
sizes and cross-talks. We found that in humans any two of the 8 
pathways can cross-talk and in humans we compared the possible 
dynamic activities of both the pathways and their cross-talks. We 
characterized tissue- and cancer-specific expression profiles, and 
identified proteins relevant for drug target discovery. 
Table 1.  Comparison of the curation processes of 3 manually curated 
databases and SignaLink. Only the differences from SignaLink are listed. 
The features setting SignaLink most clearly apart have a grey background. 
 KEGG Reactome NetPath SignaLink 
Source of 
Signaling 
Proteins 
Selective 
manual  
curation  
from the 
literature 
Reaction- 
based 
manual 
curation 
Selective 
manual 
curation 
from HPRD 
Manual curation: 
pathway-based 
reviews,  
experimental  
papers 
Source of 
Interactions 
Only 
reviews 
PubMed ID 
available for 
each 
interaction 
PubMed ID 
reaction  
details for  
each  
interaction  
PubMed ID 
listed for each 
interaction 
Number of 
Signaling 
Pathways 
10  
(no NHR) 
10, but not 
for all species  
(no Hh ,NHR, 
JAK/STAT) 
20 (no  
WNT, IGF,  
NHR,  
JAK/STAT) 
8 (EGF/MAPK, 
WNT, TGF,  
Notch, IGF, Hh,  
NHR, JAK/STAT)
Definitions  
of Pathways 
Not  
available 
Not  
available; 
uniform 
curation  
rules 
Cancer or 
immune 
pathways 
Biochemically 
defined; important 
in development; 
uniform curation  
rules; documented 
in detail 
Pathways in  
one 
platform for 
cross-talk 
analysis 
Not 
possible 
Possible, but 
no global 
pathway view  
or common 
platform 
Not 
possible 
Possible 
2 SYSTEM AND METHODS 
2.1 Signaling proteins and interactions 
SignaLink lists signaling proteins and directed signaling interactions 
between pairs of proteins in healthy cells of Caenorhabditis elegans, 
Drosophila melanogaster, and Homo sapiens. Each interaction is 
documented with the PubMed ID of the publication reporting the verifying 
experiment(s). SignaLink was compiled separately for all pathways of the 3 
organisms. Search functions, data, and network images of the pathways are 
available at http://SignaLink.org. 
In each of the 3 organisms we first listed signaling proteins and interactions 
from reviews (and from WormBook in C. elegans) and then added further 
signaling interactions of the listed proteins. To identify additional 
interactions in C. elegans we examined all interactions (except for 
transcription regulation) of the signaling proteins listed in WormBase 
(Rogers et al., 2008) and added only those to SignaLink that we could 
manually identify in the literature as an experimentally verified signaling 
interaction. For D. melanogaster we added to SignaLink those genetic 
interactions from FlyBase (Drysdale, 2008) that were also reported in at 
least one yeast-2-hybrid experiment. For humans we manually checked the 
reliability and directions for the protein-protein interactions found with the 
search engines iHop and Chilibot (Chen and Sharp, 2004; Hoffmann and 
Valencia, 2004). 
SignaLink assigns proteins to signaling pathways using the full texts of 
pathway-reviews (written by pathway experts). While most signaling 
resources consider 5-15 reviews per pathway, SignaLink uses a total of 170 
review papers, i.e., more than 20 per pathway on average. Interactions were 
curated from a total of 941 articles (PubMed IDs are available at the 
website). We added a small number of proteins based on InParanoid 
ortholog clusters (Berglund et al., 2008). For curation we used a self-
developed graphical tool and Perl/Python scripts. The current version of 
SignaLink was completed in May 2008 based on WormBase (version 191), 
FlyBase (2008.6), Ensembl (49), UniProt (87), and the publications listed 
on the website. Pathway data can be downloaded in several formats: SQL, 
CSV, XLS, CYS and SVG exported from Cytoscape, and SBML. 
2.2 Quality control, database validation, statistical 
significance tests 
The curation protocol of SignaLink (Fig. 1A) contains several steps aimed 
specifically at reducing data and curation errors. We used reviews as a 
starting point, manually looked up interactions three times, and manually 
searched for interactions of known signaling proteins with no signaling 
interactions so far in the database. The section “Advantages and limitations 
of SignaLink” explains validation steps and results in detail. We performed 
functional significance tests for each of the signaling pathways and their 
overlaps, i.e. multi-pathway proteins, with the ‘GO Termfinder’ toolbox 
(Boyle et al., 2004). We found a significant functional similarity between 
the functions of multi-pathway proteins and the functions of their pathways 
compared to the control case (functional similarity between the functions of 
all proteins and all pathways). Moreover, we statistically evaluated the 
human interactions listed in SignaLink with the PRINCESS web service (Li 
et al., 2008) and found that the ratio of high confidence interactions is 
90.6%. Details for all statistical significance tests are available in the 
Supplementary Data. 
2.3 Expression in selected healthy tissues and liver 
carcinomas 
To investigate the dynamic activity of pathway interactions, we selected 
five healthy tissue types – colorectal, muscle, skin, liver, and 
cardiovascular tissues – and 2 liver carcinomas (Fig. 3, see the details for 
the selection process of the tissues and controls in the Supplementary Data 
file. Protein expression data in healthy tissue types were downloaded from 
the eGenetics database (integrated into Ensembl). Protein expression data 
in 2 screens of liver carcinomas were obtained from Oncomine 3.6 (Rhodes 
et al., 2007). We considered a protein differentially expressed if the p value 
of its expression in at least one of the 2 screens, as compared to healthy 
liver tissues and computed by a t-test of Oncomine, was below 0.05. 
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Fig. 1. Basic information about SignaLink. (A) The manual curation process. (B) Weighted protein numbers of SignaLink in the 8 signaling pathways of the 
3 investigated species. (C) Weighted interaction numbers within pathways and between pathways (cross-talks). See the Supplement for details. 
2.4 Functional annotation of drug target candidates 
We collected information on the proteins that can be relevant in drug target 
discovery with DAVID (Dennis, Jr. et al., 2003). We downloaded disease-
related annotations from OMIM, GAD, and Orthodisease (Amberger et al., 
2009; Becker et al., 2004; O'Brien et al., 2004), domain information from 
InterPRO (Hunter et al., 2009), and molecular function and cellular 
component data from GO (Harris et al., 2004). 
3 RESULTS 
3.1 Uniform compilation of signaling pathways in 
three metazoan species 
We curated the signaling pathways of the nematode 
Caenorhabditis elegans, the fruit fly Drosophila melanogaster, 
and Homo sapiens. From the wide variety of classification schemes 
for selecting signaling pathways (Bader et al., 2006) we followed 
the biochemical approach of Pires-daSilva and Sommer (Pires-
daSilva and Sommer, 2003). We selected 8 major pathways for 
curation – EGF/MAPK, Ins/IGF, TGF-β, WNT, Hh (Hedgehog), 
JAK/STAT, Notch, and NHR (Nuclear Hormone Receptors) – that 
have central roles both in development and in normal cellular 
signaling. 
SignaLink is a manually compiled resource integrating 
experimentally confirmed genetic and physical interactions from 
healthy tissue types. Proteins and interactions are listed without 
tissue-specificity and can be visualized as networks of potential 
interactions. Tissue- and disease-specific information can be added 
easily as shown in the examples below. Five combined 
characteristics create the unique utility of SignaLink:  
(1) Pathways are biochemically defined and encompass all 
major developmental signaling mechanisms; 
(2) A protein can belong to more than one pathway (if it does, 
then it is called a multi-pathway protein); 
(3) Proteins are tagged with (i) the pathway(s), (ii) pathway 
region(s) (core, peripheral), and (iii) the pathway sections 
(one or two of: ligand, receptor, mediator, co-factor, 
transcription factor, other) they belong to; 
(4) The level of detail is the same for the entire database; 
(5) Interactions are directed and manually labeled with 
PubMed IDs (experimental evidence). 
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Currently, SignaLink lists 560 proteins and 237 interactions from 
C. elegans, 344 proteins and 233 interactions from D. 
melanogaster, and 646 proteins with 991 interactions from 
humans. Similarities and differences between species and 
pathways are shown in Figs. 1B and 1C. The database, its help 
pages, a detailed description of the curation process, and network 
visualizations of all pathways are available at http://SignaLink.org. 
Fig. 2. Maps of signaling cross-talk in three metazoans integrating 
manually curated data from healthy tissue types. Pathway cores are 
indicated by darker colors. The width of a link between two pathways is 
proportional to the (weighted) number of directed signaling interactions 
(cross-talks) between the two pathways. A directed signaling interaction 
between two proteins annotated to n and m pathways, respectively, adds 
1/(nm) to the weight between any two of the directed pathway pairs 
connected by this interaction. Two oppositely directed interactions are 
counted separately. (A-C) Cross-talks, i.e., signaling interactions between 
pathways. Note that in humans any two pathways can cross-talk. (D-F) 
Cross-talk by pathway sections. In humans cross-talk is ubiquitous even 
among pathway sections, while in the other two species mostly co-factors 
and mediators cross-talk. See Methods for details and http://SignaLink.org 
for data sets. 
3.2 A large-scale view of species-specific pathway and 
pathway section sizes 
In all 3 organisms a few of the 8 pathways are central and 
abundant. Of all proteins 26% to 38% participate in the 
EGF/MAPK and WNT pathways, respectively. Other pathways 
with high protein numbers are NHR in the worm, Hh and Notch in 
the fly, and TGF and JAK/STAT in humans. Altogether in each 
species 68% to 85% of all signaling proteins participate in these 
pathways and 56% to 70% of all cross-talks involve the 
EGF/MAPK, TGF, or WNT pathways. C. elegans has almost 
identical numbers of core and peripheral proteins in each pathway 
(except for Notch and NHR), while in the other two species the 
ratio of core to peripheral proteins is around 1.5. 
Pathway size differences between the 3 species are often related to 
the different environments to which the cells of these organisms 
have adapted. For example, ligands from the environment can 
easily reach the nuclei of the worm’s cells, thus, the worm’s NHR 
pathway is exceptionally large (58% of all signaling proteins). On 
the other hand, due to the large variety of signals that human cells 
are exposed to the human JAK/STAT pathway is oversized 
compared to the other two species (21% of all signaling proteins in 
humans vs. 0% and 4% in C. elegans and Drosophila, 
respectively). 
In all 3 species EGF/MAPK and IGF have high numbers of 
mediators. However, environmental differences may affect 
pathway section sizes too. In C. elegans transcription factors – 
dominated by the NHR pathway – are the largest pathway section 
(39%). In the other two species co-factors by far outnumber other 
pathway sections (32% to 42%) and in humans JAK/STAT ligands 
and receptors are abundant.  
3.3 Multi-pathway proteins: Proteins functioning in 
more than one signaling pathway 
In C. elegans, D. melanogaster, and humans, we found 6, 12, and 
62 multi-pathway proteins, respectively. Within one human 
signaling pathway the ratio of proteins functioning in at least one 
other pathway varies from 5% (Notch) to 46% (IGF). Interestingly, 
a single protein can be even a central (i.e., core) component in 
more than one pathway. For example, the scaffold protein AXIN 
and the kinase GSK3 are both core components of more than one 
signaling pathway (Luo and Lin, 2004; Frame and Cohen, 2001). 
We found that EGF/MAPK – the largest pathway – is the only one 
sharing proteins with all other pathways. On the other end of the 
spectrum are the Notch, JAK/STAT, and NHR pathways: their 
proteins are contained by 3 or 4 other pathways. These differences 
correlate well with the numbers of pathway functions. Note also 
that the set of 62 human multi-pathway proteins is enriched with 
disease-related proteins: 45% (28) of them are known to be 
disease-related, while in the 8 human signaling pathways only 
25.5% (165 of 646) and among all human proteins listed by 
Ensembl only 20% (3,929 of 19,534). For both comparisons p < 
0.001. 
3.4 Cross-species comparison of cross-talks 
Next, we focused on how the complexity of intracellular signaling 
increases with a growing complexity of the organisms. In C. 
elegans only 6 of the 8 curated pathways are active, and the Notch 
pathway is isolated (Fig. 2A). In addition, the cross-talk network of 
the pathways – where nodes represent pathways and links 
represent cross-talks – is sparse. Between the 6 active pathways 
only 5 of the 30 ( = 6×5 ) possible cross-talk types are present. In 
Drosophila all 8 curated pathways of SignaLink are active, but the 
NHR and JAK/STAT pathways are still isolated. Without these 
two pathways the cross-talk network is already significantly denser 
than in the worm: 16 of the total 30 possible cross-talk types are 
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present (Fig. 2B). In humans – the most complex organism of the 
three – all 8 curated signaling pathways are active and almost all of 
the 56 possible cross-talk types are possible (Fig. 2C). The 
ubiquity of cross-talks (all 28 pathway pairs can cross-talk) 
expands both the repertoire of possible phenotypes and the system-
level responses to environmental and pathological changes. 
In C. elegans cross-talk is possible through receptors, mediators, 
and transcription factors (Fig. 2D). In the other two species all 
pathway sections can participate in cross-talk, except for the NHR 
and JAK/STAT pathways of Drosophila, where cross-talk occurs 
mostly at the transcriptional level and through mediators, 
respectively (Figs. 2E-F).  
Fig. 3. Possible dynamical activity of the signaling interactions between 
and within pathways in (A) 5 selected healthy human tissue types and (B) 2 
human liver carcinomas. (A) In the selected healthy tissue types the 
pathways EGF/MAPK, WNT, TGF, and IGF have the potential to cross-
talk most frequently, while the cross-talk connections of the Notch pathway 
have less potential to be active. (B) In the two investigated liver carcinomas 
signaling interactions within the EGF/MAPK, WNT, and TGF pathways 
and their cross-talks are most extensively changed while the cross-talks of 
the Notch pathway are the least affected. See text for details. 
In addition to the number of active pathways and cross-talks a 
further important indicator of signaling complexity is the number 
of cross-talks relative to all signaling interactions. In the worm 
4.6% of all signaling interactions are cross-talks, in the fly 10.5%, 
and in humans 30.3%. Interestingly, the growth of the number of 
cross-talks from worm to fly and human is not simply due to the 
growth of the number of protein-coding genes (20 100, 13 800, 23 
000, respectively) or the number of signaling-related PubMed 
articles (3 889, 11 367, 214 193 in worms, flies, and humans, 
respectively). 
The presence of cross-talks in many pathways and pathway 
sections is a sign of the efficient utilization of resources: expanding 
the functions of an already existing pathway protein is more 
efficient than evolving a novel protein (Bhattacharyya et al., 2006). 
Given the high number of signaling cross-talks, a large variety of 
specific and robust phenotypes may emerge (Taniguchi et al., 
2006). However, the actual signaling responses are controlled 
mainly by scaffold proteins, feedback loops, kinetic insulation, and 
the spatial and temporal expression patterns of proteins (Behar et 
al., 2007; Bhattacharyya et al., 2006; Kholodenko, 2006; Freeman, 
2000). To map some of these possibilities, we investigated the 
dynamical activity of signaling cross-talks in humans where cross-
talk was found ubiquitous. 
3.5 Tissue- and disease-specific activity of cross-talks 
Cross-talks, similar to other protein-protein interactions, are not 
active permanently in all tissue types. We considered an interaction 
to be possibly active in a given tissue type, if both of the mRNAs 
of its participating proteins are expressed in that tissue. It is 
reasonable to assume (as a simple approximation) that proteins 
whose mRNAs are expressed could be active in the given tissue 
(compared to those that are not transcribed). After merging 
SignaLink with protein expression profiles from human colorectal, 
muscle, skin, liver, and cardiovascular tissues, we quantified the 
possible tissue-specific activity of cross-talks. We found that cross-
talks between the pathways EGF/MAPK and TGF, and cross-talks 
from WNT to TGF and from EGF/MAPK to JAK/STAT are 
overrepresented (Wald-test, upper limit: 7.25%) The complete 
statistical test is available in the Supplementary Data. In addition, 
we found that (i) the Notch and NHR pathways are the least 
connected to other pathways, and (ii) Notch and JAK/STAT are 
the least and most frequently used pathways, respectively: on 
average 26% and 48% of their proteins are expressed in the 
selected healthy tissue types (Fig. 3A).  
Cancers are often viewed as systems diseases (Hornberg et al., 
2006). In cancer cells large-scale modifications of signaling 
pathways, especially changes of cross-talks (Stelling et al., 2004), 
are prevalent. Accordingly, detecting which proteins (cross-talks) 
are differentially expressed (active) in a carcinoma tissue may 
point out key causes of the given tumour and can help the 
identification of novel, systems-based drug targets (Korcsmaros et 
al., 2007; Tortora et al., 2004). To do this we merged the network 
of 8 human signaling pathways with protein expression data from 
human liver carcinomas. We considered a signaling interaction to 
be altered in these two liver carcinomas, if, compared to healthy 
liver tissues, at least one of the participating proteins was 
differentially expressed (see Methods for details). In 3 of the 8 
pathways (WNT, NHR, and JAK/STAT) only ~30% of all proteins 
were differentially expressed in the investigated liver carcinomas, 
while in the other 5 pathways this ratio was ~50% (Fig. 3B).  
In summary, the largest signaling pathway, EGF/MAPK, is 
frequently used in the selected tissue types and significantly 
changed in the two liver carcinomas. JAK/STAT is also strongly 
used, but less modified in the two investigated liver carcinomas. A 
third example is Notch, which is neither strongly used nor strongly 
modified. Thus, even though cross-talks are possible between all 
pairs of investigated human signaling pathways, the possible 
Korcsmáros et al. 
6 
activity of these pathways in healthy tissues and the modifications 
of their cross-talks in the analyzed cancer types are highly diverse. 
See the Supplementary Data for additional literature support. 
 
3.6 Potential role of cross-talking proteins in drug 
target discovery  
Signaling proteins are overrepresented among human disease 
genes (Sakharkar et al., 2007) and are intensively studied as 
potential drug target candidates (Chaudhuri and Chant, 2005), 
often with network-based methods (Berger and Iyengar, 2009). 
Among the 62 human multi-pathway proteins 21 (33.8%) are 
known drug targets compared to 15% (94 of 646) in all 8 pathways 
and 8.2% (1 610 of 19 534) among all human proteins. This 
implies that the remaining set of 41 human multi-pathway proteins 
may also be relevant for drug target discovery. In summary, the 
following two sets, altogether 327 proteins in our current study, are 
likely to be enriched with possible drug targets: (i) human multi-
pathway proteins and (ii) proteins participating in cancer-related 
cross-talks. 
 
Fig. 4. Analysis of drug target candidate proteins listed with SignaLink. A) 
The numbers of membrane proteins (m), enzymes (e), proteins with kinase 
domains (k), and disease-related proteins (d) among the 3 groups of 
proteins listed in SignaLink as possible novel drug targets (control: all 
SignaLink proteins). B) Proteins with a fixed number of key properties out 
of the listed 4 (m, e, k, d). For each group the number of drug target 
proteins is shown separately. The names of the most promising candidates 
(all 4 key properties, not yet targeted) are listed. 
 
We analyzed the drug target relevance of human signaling proteins 
by examining 4 key properties: disease-relatedness, localization in 
the plasma membrane (Gao et al., 2008; Yildirim et al., 2007), 
enzymatic functions, and kinase domain content (Fabbro et al., 
2002). To identify the most promising drug target candidates from 
the 327 proteins selected in the previous paragraph, we first listed 
those 9 that have all 4 key properties, i.e., disease-related enzymes 
(with a kinase domain) localized in the membrane (Fig. 4). Out of 
these 9 proteins 5 (CASK, EGFR, ErbB2, IGF1R, and INSR) are 
currently used as drug targets, while the other 4 (IRAK1, 
MAP3K13/LZK/MLK, ROR2, and TGFBR1) are not. ROR2 is 
essential during bone formation (Liu et al., 2007) and the other 3 
proteins are inflammation-related factors (Klein et al., 2001). 
Interestingly, ROR2 was recently suggested as a therapeutic target 
for osteosarcoma based on expression analysis and siRNA 
treatment (Morioka et al., 2009). As for IRAK1, TGFBR1, and 
MLK, anti-inflammatory drugs (imiquimod, dexamethasone, and 
L-arginine, respectively) frequently affect their pathways, but 
without sufficient specificity (Klein et al., 2001). These findings 
support our predictions that these 4 human signaling proteins are 
promising novel drug targets.  
DISCUSSION 
4.1 Advantages and limitations of SignaLink 
According to a recent study (Cusick et al., 2009), manual curation 
projects (i) inherit the selection biases of the curated experiments, 
(ii) often lack the specific goals clearly defining the curation 
criteria, and (iii) it is usually difficult to estimate their 
completeness and reliability. Note, however, that many signaling 
proteins function outside the cell (ligands), in membrane-bound 
positions (receptors), or in the nucleus (transcription factors), and 
that proteins from these compartments are underrepresented in 
current high-throughput (HTP) data. Thus, for the purpose of 
identifying signaling proteins and interactions HTP techniques 
seem to be less adequate than those manual curation projects that 
have clear goals. In the case of SignaLink the precisely defined 
curation process combines original research articles and reviews, 
thus, both experimental evidence and its critical discussion by 
specialists are included. 
Applying a biochemically-based, well-documented, and clear 
pathway definition is central to SignaLink. For example, the 
EGF/MAPK pathway in SignaLink contains (with evolutionary 
and biochemical reasoning) the pathway from the EGF ligand to 
the terminal MAPK kinases. In several other databases this 
pathway is scattered across many separate (sub)pathways (e.g., 
EGFR, RAS, p38, JNK, ERK, ASK). An important consequence of 
precise pathway definitions is the reduced number of examined 
pathways. We suggest that appropriate and precise grouping, to 
avoid artificial pathway constructs, may be a better indicator of the 
goodness of the resource than merely the large number of 
pathways. 
Of the constantly increasing number of signaling databases (Bader 
et al., 2006) many are proprietary, list fewer than 200 molecules, 
or only selected types of pathway components, e.g., protein 
kinases. Even among the few databases passing these criteria (free 
for academic use, more than 200 molecules, all pathway 
component types included) there are currently no gold standards 
compiled with similar goals and methods as SignaLink. It is 
therefore important to compare both the curation protocols and the 
actual data of several available databases before selecting one of 
them for a particular analysis. In Table 2 we compare three widely 
used pathway databases – KEGG, Reactome, and NetPath – and 
SignaLink (see the Supplementary Data file for details). In each 
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pairwise comparison we used the pathways available in both 
databases. 
According to Table 2 and the Supplementary Data, SignaLink has 
the following advantages compared to the three analyzed 
databases: (1) precisely defined and documented curation protocol; 
(2) highest numbers of signaling proteins and interactions in the 
curated signaling pathways; (3) highest numbers of cross-talks and 
multi-pathway proteins; (4) largest protein overlap with the other 
databases; (5) above the average number of publications used per 
pathway; (6) minimal usage of protein isoform names; (7) no 
binary interactions inferred from the membership of two proteins 
in the same complex; (8) low number of proteins from 
UniProt/TrEMBL (i.e., few unverified proteins). SignaLink was 
compiled based on pathway reviews and primary research articles. 
Thus, the high numbers of signaling proteins (including multi-
pathway proteins) and cross-talks are likely to be dominated by 
true positives, indicating higher precision and coverage. 
 
Table 2.  Comparison of database content for human pathways between 3 
manually curated databases and SignaLink. In each pairwise comparison 
we compared only the pathways curated in both databases. 
 KEGG Reactome NetPath SignaLink 
 Pathways MAPK, 
Insulin, 
Hedgehog, 
JAK/STAT, 
Notch,  
TGF-β,WNT 
EGFR, 
Insulin  
receptor, 
Notch,  
TGF,  
WNT 
EGFR1,  
Hedgehog,  
Notch, 
TGF, WNT 
EGF/MAPK,  
IGF, Hh, 
JAK/STAT, 
Notch, NHR, 
TGF, WNT 
Number of proteins and interactions* 
Proteins 429 (483) 56# (348) 362 (355) 646‡ 
Interactions 1,502+ (990) 682# (689) 457 (701) 991 
cross-talks 225+ (228) 79# (226) 60 (171) 300× 
Number of 
publications* 73 166 351 941 
In KEGG only protein complexes and their interactions were available and we 
constructed a list of binary interactions, i.e., a network, with the “matrix” method 
(Bader and Hogue, 2002). Symbols: * For the same pathways in SignaLink: EGFR, 
EGFR1, and MAPK are compared to the EGF/MAPK pathway of SignaLink; # binary 
interactions from membership in the same complex; ‡ including predicted pathway 
member proteins; + for each directed interaction between two protein groups (KEGG 
complexes) we added a directed link between each protein of the source group and 
each protein of the target group; ×weighted cross-talk interaction number: a directed 
signaling interaction between two proteins annotated to n and m pathways, 
respectively, adds 1/(nm) to the weight between any two of the directed pathway pairs 
connected by this interaction. See the Supplementary Data for further details. 
Despite the care we have taken in creating SignaLink, it does have 
limitations, e.g., SignaLink does not contain all signaling proteins. 
Only those signaling proteins have been included that have an 
experimentally verified function in the selected 8 major pathways 
or a directed interaction with at least one of their proteins. Several 
groups of proteins were fully excluded from SignaLink. These 
groups, together with our detailed reasons for excluding them, are 
listed in the Supplementary Data. The compilation of SignaLink 
was based on published review and research papers. Note that the 
curation of the current version of SignaLink was closed in May 
2008. Naturally, more pathways (defined by the same evolutionary 
and biochemical rules) and proteins can be added in a future 
version. We plan to update SignaLink every July (starting 2011). 
The next update will include recent high-confidence high-
throughput data. Overall, based on the comparison we presented in 
this sub-section, we expect that the limitations of SignaLink are 
small compared to the improvements it can provide. 
 
 
 
4.2 Current applications 
The primary goal of SignaLink is to provide maps of global 
pathway communication in 3 metazoans (C. elegans, D. 
melanogaster, and H. sapiens) with well-documented, uniform 
manual curation. Interactions from all healthy tissue types were 
included into SignaLink, and expression data from selected tissues 
were used for dynamic analysis. We found that the pathways 
EGF/MAPK, JAK/STAT, and Notch are clear examples for three 
distinct types of behavior: (i) high expression in normal tissue 
types and strong changes in cancer, (ii) high expression, but small 
changes, and (iii) low expression and small changes. See the 
Supplementary Data for additional literature support. 
Network analyses – combined with system-level resources – can 
contribute to modern drug target discovery, e.g., to 
polypharmacology and multi-target drug selection (Hopkins, 2008; 
Korcsmaros et al., 2007). With SignaLink one can prioritize novel 
drug target candidates by examining the list of (i) multi-pathway 
proteins and (ii) proteins participating in cancer-related cross-talks. 
Some of these proteins could be specific and proper targets, some 
of them could be too central and aspecific After listing the 
properties of these proteins relevant for drug target selection, we 
suggested 4 novel drug target candidates. One of them, ROR2, was 
recently proposed as a novel chemotherapeutic target, while the 
other 3 are known to be non-specifically affected by anti-
inflammatory drugs. A broader list contains 35 additional proteins 
with a lower confidence, which may be again filtered with 
additional criteria, e.g., phosphatase activity.  
In biomedical experimental work the functions of a few selected 
proteins are often modified. These changes can unexpectedly 
perturb signaling pathways and non-specifically affect cellular 
processes. Based on several data sources, including SignaLink, we 
have launched a web server, PathwayLinker, to aid experimental 
work by linking the queried proteins to signaling pathways through 
physical and/or genetic interactions (Farkas et al., submitted). 
4.3 Future applications 
As their name suggests, targeting multi-pathway proteins may not 
be selective. However, selectivity is a key property in 
pharmacology, thus, analyses of multi-pathway proteins could 
support drug target discovery. Based on SignaLink we suggest 
single-gene knock-out experiments or RNA silencing of individual 
cross-talking proteins to help understand the functional selectivity 
of signaling pathways and to reduce the redundancies that are 
assumed to make many currently used drugs less efficient (Urban 
et al., 2007; Tortora et al., 2004). 
For the mathematical modeling of the dynamical behavior of 
biomolecular pathways the precise, high-coverage reconstruction 
of the static network structure of these pathways is crucial (Papin 
et al., 2005). In the case of signaling pathways the manual curation 
of the existing literature can be efficient for assembling large-scale 
interaction maps. SignaLink data sets have a simple and uniform 
structure and are available in several formats for all 8 pathways 
and 3 species at http://SignaLink.org. This allows one to easily 
merge SignaLink with stoichiometric and expression data from, 
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e.g., perturbation analyses (Papin et al., 2005). The static network 
provided by SignaLink can serve as a backbone for both numerical 
and differential equation-based models and – due to SignaLink’s 
focus on cross-talks – for deciphering the rules of cooperation 
between pathways (Wang et al., 2009; Borisov et al., 2009). 
Finally, perturbation analyses that cannot be carried out with HTP 
protein-protein interaction (PPI) networks (they list undirected 
PPIs), may be manageable with SignaLink, because it contains the 
directions of interactions. 
A central goal of synthetic biology is to engineer cells that can 
carry out novel tasks (Friedland et al., 2009; Bhattacharyya et al., 
2006). One way to achieve this goal is to rewire signaling circuits 
by modifying scaffold proteins and other biomolecules or by 
changing feed-back loops. In these studies detailed high-quality 
maps of intracellular signaling are essential, especially the 
positions of cross-talks and multi-pathway proteins. 
Comparative evolutionary studies usually focus on conserved and 
altered mechanisms underlying the observed differences in body 
plans. Among metazoans these differences are largely due to 
changes in the complexity of regulation rather than different gene 
numbers (Levine and Tjian, 2003; Szathmary et al., 2001). Two 
decisive regulatory networks in this case are transcriptional control 
and signaling, in particular, cross-talks. SignaLink was compiled 
with uniform curation rules for 8 major pathways in 3 metazoans 
that have similar signaling mechanisms but different morphologies. 
Therefore, the data sets of SignaLink are well applicable to 
studying evolutionary changes. 
4.4 Conclusions 
Contrary to earlier views, signaling pathways are now understood 
as interlinked (not linear) routes heavily interlinked by cross-talks. 
This major paradigm shift necessitates novel, systems-based 
approaches, e.g., new techniques for curation and modeling. 
Attempting to meet the novel curation requirements, we have 
compiled a signaling pathway resource, SignaLink. It allows the 
systematic comparison of pathways and their cross-talks. After 
finding that any two of the 8 selected human signaling pathways 
may cross-talk, we quantified the possible activity patterns of these 
cross-talks in healthy and cancerous human tissues. Large-scale 
mapping of pathways and the activity patterns of their cross-talks 
revealed multi-pathway and cancer-related cross-talking proteins 
that can be relevant for drug target discovery. 
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Supplementary results and data 
Comparison of pathways across species 
 
On the system level one may observe that the worm has more signaling proteins than the fly, 
which is mostly due to the large number (more than 250) of nuclear hormone receptors (NHR) 
in the worm. As for single pathways, note that in the worm several proteins orthologous to fly 
and human JAK/STAT and Hh pathway member proteins are expressed. However, only few 
interactions of these proteins have been experimentally verified so far (Burglin and 
Kuwabara, 2006). In other words, experimental evidence cannot support yet that in C. elegans 
these two pathways are functional. It has been suggested that the pathways JAK/STAT and 
Hh disappeared from the worm during its evolution (Pires-daSilva and Sommer, 2003). A 
comparison of pathways between the three species shows also that in all three the largest 
pathway (containing the largest number of proteins) is the EGF/MAPK pathway, while the 
next three (in the order of protein number) are WNT, TGF, and IGF, respectively. In C. 
elegans and D. melanogaster the total weighted number of proteins1
A look at the internal structure of the eight curated signaling pathways reveals further details. 
See the accompanying website, 
 in these four pathways is 
approximately the same (154.5 and 117.3 proteins, respectively), while in humans the total is 
approximately twice this number (295.2). As a contrast, the Hh and Notch pathways have 
very similar protein numbers in all three species. Note that in humans four (EGF/MAPK, IGF, 
JAK/STAT, and WNT) of the five largest pathways are kinase-based pathways. 
 
http://SignaLink.org, for detailed statistics, a detailed curation 
manual, and zoomable images of the 8 curated pathways in all 3 organisms. In humans the 
backbone (core region2
Because of the large number of its experimentally known genetic interactions, the fly has 
currently many more known interactions among its signaling proteins than the worm. 
However, experimental approaches have not yet verified a large portion of the genetic 
interactions in the fly as true physical interactions, and so the evidence provided by genetic 
interactions is less direct than other evidence types. Thus, before inserting genetic interactions 
into SignaLink, we have carefully filtered them, mostly by searching for other types of 
) of the EGF/MAPK pathway is significantly stronger due to the high 
number of parallel MAPK cascades. Similarly, the backbone of the WNT pathway is notably 
larger in humans than in the other two species, which is caused mainly by the high numbers of 
receptors and ligands. As a contrast, in the IGF, Hh, Notch, and TGF pathways the ratios 
between the sizes of pathway regions (core and periphery) are almost identical in the three 
species (in the Notch pathway the core region is small). The JAK/STAT pathway changes 
strongly across the three investigated species. In C. elegans the pathway is not present, in 
Drosophila it has a few proteins (a similar number of core and peripheral proteins) while in 
humans it is already comparable in size to the largest pathways and its core region is larger 
than its peripheral region. The large number of human JAK/STAT pathway member proteins 
and the strong core region of this pathway are mainly due to the high number of ligands 
(cytokines) and their receptors allowing this pathway to produce a combinatorially large 
repertoire of immune responses. In other words, the change of the size and structure of the 
JAK/STAT pathway reflects a major functional change: acquiring a central role in immune 
responses. 
 
                                                 
1 A protein participating in n pathways adds 1/n to the weighted number of proteins in each of these pathways. 
2 For an explanation of the term “core” see below in this document under “Manual curation process of 
SignaLink”. 
evidence available for the same interactions. See below under “Manual curation process of 
SignaLink” for a description for interaction evidence types. As a result in SignaLink the 
signaling interactions of the fly and the worm have similar levels of confidence and their total 
numbers are close too. 
As the fly is a more complex organism than the worm, one may expect that the number of 
high-confidence protein-protein interactions in it, including directed signaling interactions, is 
larger than in the worm. Consequently, we expect that many of the genetic interactions in the 
fly will be experimentally verified in the near future as true physical protein-protein 
interactions, many of them as cross-talks (i.e., signaling interactions between pathways). 
 
 
Statistical significance tests of cross-talk numbers 
 
We have determined the adjusted Wald Confidence Interval to find the pairs of pathways 
between which pathway-pathway connections (i.e., cross-talks) are more frequent than the 
others (Agresti and Coull, 1998). With the adjusted Wald confidence interval we determine 
the 95% confidence interval, supposing binomial distribution of the cross-talks. If the number 
of cross-talk lies out of this 95% confidence interval, we may say that the particular pathway 
connections are more frequent. Supplementary Table 1 shows the relative frequencies of the 
interaction numbers between pairs of human signaling pathways in SignaLink. Note that this 
table shows only the 10 highest scoring directed pairs of pathways. Based on the full list of 56 
( = 8 * 7 ) directed pairs of pathways the average of the relative frequency is is 1.79% the 
upper border of the adjusted Wald confidence interval lies at 7.27%. 
 
 
Directed cross-talk 
between pathways 
Number of 
interactions 
Relative 
frequency 
 
IGF EGF/MAPK 36 3.10%  
EGF/MAPK IGF 50 4.31%  
EGF/MAPK WNT 53 4.57%  
TGF WNT 57 4.91%  
WNT EGF/MAPK 65 5.60%  
JAK/STAT EGF/MAPK 83 7.16%  
EGF/MAPK JAK/STAT 90 7.76% Statistically 
significantly 
overrepresented 
WNT TGF 90 7.76% 
TGF EGF/MAPK 104 8.97% 
EGF/MAPK TGF 160 13.79% 
Supplementary Table 1. Wald statistical scores of the interaction numbers between the 8 human signaling 
pathways in the SignaLink database. Only the 10 directed pathway pairs with the largest scores are shown here. 
Relative frequencies above 7.25% are statistically significant (see text above for details). 
 
Analysis of cross-talks in each species 
 
In this section we first define cross-talks. Then we describe and discuss active pathways in the 
three organisms. Last, we show examples for cross-talking pairs of pathways. 
The classical definition of cross-talk assumes that each protein is contained by exactly one 
signaling pathway. According to this definition, if proteins A and B belong to different 
signaling pathways, then the signaling interaction between proteins A and B is a cross-talk 
between their signaling pathways. SignaLink – and several other databases too – provide a 
more precise mapping of signaling pathways and allow that a signaling protein belongs to 
more than one pathway. Therefore, the classical definition of cross-talk has to be extended. A 
signaling interaction between two proteins, A (contained by pathways a1, a2, ...) and B (b1, b2, 
...), is at the same time a cross-talk between each pair of different a-b pathways, i.e., between 
any pathway pair ai-bj, supposed that these two pathways are different. Of course, the 
signaling interaction between proteins A and B is a signaling interaction within each such ai 
pathway that is listed among the bj pathways as well. 
As an example consider a signaling network containing a total of four signaling proteins – A, 
B, C, and D – and two directed signaling interactions: AB and CD. Assume that in this 
example network protein A is contained by the pathways EGF/MAPK and Hh, protein B is 
contained by the pathways EGF/MAPK and WNT, protein C is contained only by the IGF 
pathway, and protein D is contained only by the Notch pathway. The directed signaling 
interaction between proteins A and B is at the same time a (directed) cross-talk between the 
pathways EGF/MAPK and WNT, a (directed) cross-talk between the pathways Hh and 
EGF/MAPK, a (directed) cross-talk between the Hh and WNT pathways, and it is also a 
(directed) signaling interaction inside the EGF/MAPK pathway. The signaling interaction 
between proteins C and D is a (directed) cross-talk between the IGF and Notch pathways. 
  
Note that if a unit weight is assigned to each of these five (directed) pathway-pathway 
interactions (one cross-talk between each of the three directed pathway pairs 
EGF/MAPKWNT, HhEGF/MAPK, and HhWNT, and one directed interaction inside 
the EGF/MAPK pathway due to the interacting (directed) protein pair AB; one cross-talk 
between the directed pathway pair IGFNotch due to the interacting (directed) protein pair 
CD), then the total weight of the signaling interaction of the (directed) protein pair AB 
would be 4 compared to the total weight of the signaling interaction of the (directed) protein 
pair CD, which would be only 1. This would incorrectly overestimate the biological 
significance of the first pair (AB) compared to that of the second pair (CD). For most 
interacting pairs of signaling proteins there is no or little quantitative information about the 
total (system-level) effect of their signaling interaction. Thus – due to the absence of such 
information – we propose that each signaling protein-protein interaction should add the same 
total weight, 1, to pathway-pathway interactions. Note that this total weight includes both 
cross-talks (ai and bj, the selected pathways of the two interacting proteins, are different 
pathways) and interactions within pathways (ai and bj are the same pathway). 
 
If in a signaling interaction at least one of the two interacting proteins belongs to more than 
one pathway, then usually there is no or little quantitative information about which one of the 
connected pathway pairs is linked more strongly by this pair of interacting proteins. 
Therefore, we propose that if a protein belongs to n pathways and another protein that it 
interacts with through a directed signaling interaction belongs to m pathways, then the 
directed signaling interaction between these two proteins should add the same weight, 1 / (n * 
m), to the cross-talk weight between any two of the directed pathway pairs connected by this 
directed signaling interaction. In the example network (defined above) the directed signaling 
interaction of proteins A and B adds a cross-talk weight of 1/4 to the three (directed) cross-
talks EGF/MAPKWNT, HhEGF/MAPK, WNTTGF, and the interaction of the 
EGF/MAPK pathway with itself, while the directed signaling interaction of proteins C and D 
adds a cross-talk weight 1 to the cross-talking (directed) IGFNotch pathway pair. 
 
Note that since protein-protein interactions are directed, two oppositely directed interactions 
between the same proteins, i.e., AB and BA, are counted separately and contribute 
separately to the interaction weights (cross-talks and within-pathway) between the directed 
pairs of their pathways. 
 
 
Active pathways and cross-talking pathways 
 
With an increasing complexity of the investigated organisms the number of active pathways 
increases and the number of cross-talking pathways also increases. In other words, the cross-
talk map of the organism becomes denser. 
 
In C. elegans only six of the eight curated pathways are active. In addition, the network of 
pathways is sparse: only 5 of the 30 possible cross-talk types (connecting the 6 active 
pathways) are present (see the supporting website for detailed statistics). Interestingly, the 
number of cross-talks in the two possible directions between the same pair of pathways is 
often different. For example, in C. elegans – according to SignaLink – the weighted number 
of directed signaling interactions pointing from the EGF/MAPK pathway to the IGF pathway 
is 1.5, while in the opposite direction (IGFEGF/MAPK) there is no signaling interaction. 
Two further examples are (i) the cross-talks between the Hh and WNT pathways in D. 
melanogaster (for HhWNT the weighted number of directed interactions is 6.9 and for 
WNTHh it is 3.1) and (ii) the human EGF/MAPK and TGF pathways where the weighted 
number of directed signaling interactions pointing towards the EGF/MAPK pathway is much 
higher as in the opposite direction (47.2 vs. 28.0). 
In Drosophila all eight curated pathways of SignaLink are active (see Fig. 2b of the main 
text), however, the NHR and JAK/STAT pathways are isolated. Without these two pathways 
the cross-talk network is already relatively dense: 16 of the total 30 possible cross-talk types 
are present. 
 
In humans all eight curated signaling pathways are active and all 28 ( = 8 * 7 / 2 ) pathway 
pairs are connected by cross-talks. As signaling interactions are directed, the 28 pairs of 
pathways allow 56 ( = 8 * 7 ) types of directed cross-talk. Of these 56 only 6 are inactive. The 
highest (weighted) number of cross-talks is between EGF/MAPK and the other four large 
pathways: WNT, TGF, IGF, and JAK/STAT. In contrast to the other two species, the NHR 
pathway is active and cross-talks with all other pathways, which is mainly due to the signaling 
interactions between Nuclear Hormone Receptor proteins and the transcription factors of the 
other pathways. 
 
 
Examples: Cross-talks in healthy human tissues 
 
To underline the importance of signaling cross-talk in the three investigated species, we list 
here first a few general examples about the role of cross-talk in organ development. Then we 
provide examples for cross-talk between two core proteins, a core and a peripheral protein, 
and two peripheral proteins. 
 
In C. elegans EGF/MAPK and WNT signaling can cooperate to establish embryonic polarity 
and to specify cell fate. The decision between reproductive and dauer development is jointly 
controlled by TGF and IGF signaling, while vulval development is determined by the cross-
talks between EGF/MAPK, WNT, and Notch signaling (Hanna-Rose and Han, 2000). The 
patterning of the Drosophila retina is cooperatively controlled by multiple pathways: Hh, 
Decapentaplegic (Dpp) from the TGF-beta family, Notch, and EGF/MAPK. Similarly, the 
development of the wing is controlled jointly by Hh, Dpp, WNT, and EGF/MAPK (Baker, 
2007). Recent studies show that the development of human hematopoietic stem cells is jointly 
controlled by the Hh, JAK/STAT, Notch, TGF, and WNT pathways (Blank et al., 2008). 
 
Interestingly, a cross-talking pathway may interact through not just one, but many of its 
pathway sections (receptor, mediator, etc.) and both pathway regions (core, periphery). In 
humans ALK-6 and ROR2 are core proteins of the TGF and WNT pathways, respectively, 
and they are both receptors (Sammar et al., 2004). Similarly, EGF/MAPK and IGF cross-talk 
through their core proteins GRB2 and IRS1 (Claeys et al., 2002), two receptor adaptor 
proteins, while EGF/MAPK, Hh, and WNT cross-talk through their core proteins RSK1 and 
GSK3 (De Mesquita et al., 2001), which are mediators (kinases). A cross-talk involving a 
core and a peripheral protein is the interaction between PIAS4 (JAK/STAT) and SMAD4 
(TGF) (Long et al., 2003), and a cross-talk between two non-core proteins is the interaction of 
CTBP1 (Notch) and HIPK2 (TGF) (Zhang et al., 2003). 
 
Multi-pathway proteins (proteins contained by more than one pathway) 
Protein numbers and examples 
During the curation process we found that several proteins are contained by more than one 
signaling pathway. We call these proteins here multi-pathway proteins. We note that multi-
pathway proteins and their possible functions were reported in (Komarova et al, 2005). In the 
worm, the fly, and humans we found a total of 6, 12, and 62 such proteins, respectively. In 
humans the eight curated pathways in SignaLink have the following numbers of multi-
pathway proteins (i.e., proteins that are contained by at least one other pathway too): 
EGF/MAPK (41), Hh (9), IGF (17), JAK/STAT (16), NHR (3), Notch (2), TGF (29), and 
WNT (22). In summary, within one human signaling pathway the ratio of multi-pathway 
proteins varies from 5% (Notch) to 46% (IGF). 
 
Supplementary Figure 1 shows the eight human signaling pathways curated in SignaLink and 
the numbers of multi-pathway proteins. Observe that EGF/MAPK – the pathway containing 
the largest number of proteins – is the only pathway that shares proteins with all other 
pathways. On the other end of the spectrum are the Notch, JAK/STAT, and NHR pathways; 
they share proteins only with 3 or 4 other pathways. 
 
We list now a few examples for human multi-pathway proteins. First, the scaffold protein 
Axin and the kinase GSK3 are both central components, i.e., core proteins, in more than one 
signaling pathway (Luo and Lin, 2004; Frame and Cohen, 2001). Second, the WNT and Hh 
pathways both contain the same essential ubiquitin ligase complex (Maniatis, 1999). 
Moreover, ubiquitin ligases highly similar to this complex tune the TGF and Notch pathways 
(Itoh and ten Dijke, 2007; Itoh et al., 2003). 
 
  
Supplementary Figure 1. In the 8 human signaling pathways curated in SignaLink there are 62 multi-pathway 
proteins. In this figure each node represents one human signaling pathway. The size of a node is proportional to 
the number of proteins contained by the pathway (represented by the node) and the width of a link between two 
nodes is proportional to the number of proteins contained by both pathways. See the text for details. 
 
Statistical significance tests: Disease-related proteins among multi-pathway 
proteins 
 
Khi-square tests showed the significance of known disease-related proteins (Amberger et al., 
2009; Becker et al., 2004; Dennis, Jr. et al., 2003) among multi-pathway proteins in  different 
sets of proteins: The set of 62 human multi-pathway proteins is enriched with disease-related 
proteins: 45% (28) of them are known to be disease-related, while in the 8 human signaling 
pathways only 25.5% (165 of 646): χ2 =10.9817; p= 0.0009. The ratio of multi-pathway 
proteins among all human proteins listed by Ensembl is only 20% (3,929 of 19,534): χ2 = 
24.0607; p= 0.9*10-6. 
 
 
Cross-talks in the selected healthy tissue types and liver carcinomas 
 
According to eGenetics (Kelso et al., 2003) in the investigated healthy human tissues 40% 
(muscle) to 52% (colorectal) of the signaling proteins listed by SignaLink are expressed. We 
obtained protein expression in two screens of liver carcinomas (Wurmbach et al., 2007; Chen 
et al., 2002) from Oncomine (Rhodes et al., 2007). In these two liver carcinomas we 
considered a protein differentially expressed if the p value of its expression in at least one of 
the two screens – compared to healthy liver tissues and computed by a t-test of Oncomine – 
was below 0.05. We found that 46% of all SignaLink proteins have a modified expression 
compared to healthy liver tissue. Despite the similar ratios of active signaling proteins and the 
possibility of cross-talk between any two pathways, cross-talks are active in a tissue-specific 
manner. This flexibility allows the development and maintenance of different phenotypes, 
even in extreme cases such as cancer. 
 
We continue with two examples for the tissue-specific expression of cross-talk types. First, 
observe in Fig. 3a of the main text that (in the selected tissue types) between the following 
pairs of large pathways the ratio of active signaling cross-talks is lower than the average: 
EGF/MAPK-IGF, IGF-JAK/STAT, EGF/MAPK-JAK/STAT, IGF-TGF, and IGF-WNT. 
Taking the pathway pair EGF/MAPK-IGF as an example, we found only two primary 
publications reporting signaling cross-talk between them (Roudabush et al., 2000; Vardy et 
al., 1995). The second sexample, standing in contrast to the first, is the following. For 3 larger 
(and several smaller) pairs of pathways cross-talk is more frequent in the investigated tissue 
types than one would assume from the sizes of the two cross-talking pathways: EGF/MAPK-
NHR, NHR-TGF, and NHR-WNT. These fields are colored red in the chart on Fig. 3a. One 
reason for the higher than average ratio of active cross-talks between these four pathways is 
that SMAD3, a likely key protein in fibrogenesis (Flanders, 2004; Roberts et al., 2001), 
participates in all four of them and it is expressed more often in the selected tissue types than 
the average signaling protein. 
 
Next, we discuss the figure on liver carcinomas (Figure 3b) of the main text. In general liver 
carcinomas are known to involve genetic mutations in the WNT and JAK/STAT pathways 
(Takigawa and Brown, 2008; Niwa et al., 2005), an increased activity of the EGF/MAPK and 
IGF pathways and their cross-talk (Desbois-Mouthon et al., 2006), and also an increased 
activity of the JAK/STAT pathway (Calvisi et al., 2006). A less known result is that several 
proteins of the Hh pathway are activated in human HCCs (hepatocellular carcinomas) (Huang 
et al., 2006). In addition to these Figure 3b of the main text shows the amount by which each 
cross-talk type is related to the investigated liver carcinomas. The cross-talks of EGF/MAPK 
with most other pathways are frequently changed (turned on or off), similarly to the 
interactions within the group EGF/MAPK-WNT-TGF-IGF. On the other hand, the cross-talk 
activity of NHR and Notch changes only weakly in the analyzed human liver carcinomas. 
(The low number of cross-talks of the Notch pathway may distort the results for this 
pathway.) 
 
Finally, we concluded that the pathways EGF/MAPK, JAK/STAT, and Notch are clear 
examples for three distinct types of signaling behavior: (i) high expression in normal tissue 
types and strong changes in cancer, (ii) high expression, but small changes, and (iii) low 
expression with small changes. Below, we show literature support for these 3 major claims. 
 
The high expression of the EGF/MAPK pathway in all selected tissue types corresponds to its 
central role in the evolution and normal function of complex signaling networks (Manning et 
al., 2002). Moreover, deregulation of its pathway members is the major cause of several 
cancer types (Amit et al., 2007). The JAK/STAT pathway is the main pathway utilized by 
immunologically important receptors, e.g., cytokine receptors. These receptors are present in 
many tissue types, and similar to other highly expressed JAK/STAT pathway members they 
receive and transmit signals from immune cells to the given cell’s nucleus (Haan et al., 2006). 
The Notch pathway is an important pathway for cell differentiation but less important in 
mature cell types, therefore most of its pathway members – many that are responsible only for 
the regulation of the pathway – are not expressed in the selected tissue types (Bolos et al., 
2007). However, the Notch pathway can be crucial in the development of liver cancer: a 
recent study showed that in normal cells it could inhibit other oncogenic pathways (e.g., 
WNT) but in liver cancer major components of the Notch pathway is downregulated (Wang et 
al., 2009b).  
 
 
The website of SignaLink: Search, Browse, and Download options 
 
At http://signalink.org the user can search for signaling proteins and interactions of C. 
elegans, D. melanogaster, and humans by protein name, UniProt ID (or accession), and 
species-specific IDs (WormBase ID, FlyBase ID, and Ensembl protein ID). Result pages 
contain the following information (all hyperlinked): protein IDs (protein name, UniProt ID, 
UniProt accession, and species-specific IDs), the roles of proteins (pathway sections: ligand, 
receptor, mediator, co-factor, transcription factor, and other; and pathway regions: core and 
peripheral), orthologous proteins, and interaction types (incoming, outgoing, within pathways, 
and between pathways, i.e., cross-talk). 
 
The user can browse the pathways in each species and view zoomable high-resolution maps 
(networks) of each pathway colored by (i) pathway sections or (ii) by pathway regions or (iii) 
by ortholog information. For pathway sections and regions networks were exported from 
Cytoscape 2.5.2 using the Cytoscape plugins GOlorize (Release date: Feb. 12, 2007) and 
BiNoM (1.0). Node colors are listed on the website. A pie chart (with GOlorize) indicates that 
the given protein belongs to more than one pathway or more than one pathway section. We 
used the following parameters for the force-directed layout algorithm producing the networks. 
Default spring coefficient and length: both -10, node mass: 6, number of iterations: 1000, 
selected integration algorithm: Runge-Kutta (minimum and maximum edge weights: 0 and a 
very large number, respectively). 
 
With the ortholog network viewer the user can explore all 8 curated signaling pathways 
separetely or together in each of the 3 species. This viewer shows the predicted pathway 
member proteins too. In all visualizations direct and indirect interactions are shown as normal 
and dashed lines, respectively. Arrows and blunted arrows stand for stimulation and 
inhibition, respectively.  
 
You can download from http://signalink.org the curated signaling pathways of each species 
separately, all pathways of one selected species, and all pathways of all three species. 
Available formats are the following. (i) All interactions in a simple Excel file; (ii) signaling 
proteins and interactions in these formats: MS Excel, CSV (comma separated values), SQL 
dump, SBML (Systems Biology Markup Language), CYS and SVG files exported from 
Cytoscape, and PNG formatted images; (iii) multi-pathway proteins listed in a plain text file 
with TAB-separated fields; (iv) predicted pathway member proteins in an MS Excel file; (v) 
the list of review papers used for compiling SignaLink, grouped by pathways, in RefMan, 
MEDLINE, and BibTeX formats; (vi) the list of most likely drug target candidates, sorted by 
the number of analyzed properties that make them possible drug targets. Note that in the 
downloadable Cytoscape CYS files proteins functioning in more than one signaling pathway 
are colored pink, because currently the parameters of GOlorize cannot yet be fully exported 
into CYS files.  
 
 
 
Supplementary methods 
Detailed description of the SignaLink database 
 
SignaLink uses 8 biochemically defined pathways important in metazoans: EGF/MAPK, 
Insulin and Insulin-like Growth Factor (IGF), TGF-β (TGF), Wingless (WNT), Hedgehog 
(Hh), JAK/STAT, Notch, and Nuclear hormone receptors (NHR). Instead of focusing on one 
particular function or phenotype, SignaLink defines each pathway by its unique combination 
of biochemical characteristics. For example, the JAK/STAT pathway has cytokine receptors, 
it is dominated by non-receptor tyrosine kinases, and its proteins frequently dimerise. Proteins 
are assigned to pathways (i) based on reviews of pathways and protein families and (ii) using 
biochemical interactions between proteins which are manually identified from the original 
publications reporting experimental evidence. 
 
For each protein SignaLink stores four identifiers: (i) the UniProt ID of the protein (e.g., 
P92172), (ii) the name of the gene (e.g., daf-7), (iii) a species-specific gene ID (for C. elegans 
and D. melanogaster) or the protein’s Ensembl ID (for humans), and (iv) an internal database 
ID (a positive integer). In addition to these each protein in SignaLink is manually tagged with 
(i) the pathway(s) it participates in (one or more of the 8 pathways curated in SignaLink), (ii) 
its pathway region(s) (core, peripheral) in each of its pathways separately and (iii) its pathway 
section(s) (one or two of: ligand, receptor, mediator, co-factor, transcription factor, and other). 
 
In SignaLink we allowed a maximum of two pathway sections for each protein. A few 
specific cases and consequences are the following. First, we note that, strictly speaking, in the 
Notch pathway most proteins have more than two roles: receptor, mediator, and transcription 
factor. However, we labelled Notch proteins only with the pathway sections receptor and 
transcription factor, and not with mediator, because when Notch proteins are mediating they 
have almost no signaling interactions. Second, in the Nuclear hormone receptor pathway we 
listed only the actual NHR proteins (each both as receptor and transcription factor) and 
considered each NHR signaling protein to belong to the core. No ligands were included, 
because in the NHR pathway ligands are not proteins, but lipids. We also skipped the co-
factors of the NHR pathway, because their function is nuclear regulation and not the 
adjustment of the signaling flow. We believe that the co-factors of nuclear hormone receptors 
and other nuclear factors, e.g., chromatin remodelling factors, should be examined in the 
transcription regulatory network, not in the network of signaling interactions, thus, they 
belong to another type of cellular database. 
 
The pathway region of a protein indicates whether it is essential in the signaling flow of the 
given pathway. Based on experimental evidence we allowed during the curation process 
explicitly that a protein belongs to more than one pathway and even (this happened rarely) 
that it is both a core and a peripheral component within the same pathway. As an extreme case 
the human protein SMAD3 belongs to four pathways and five regions within those four 
pathways: EGF/MAPK (core), WNT (both core and peripheral), TGF (core), and NHR.  
 
In SignaLink each interaction is manually tagged with the PubMed ID of the original 
publication reporting experimental evidence for the interaction. This is necessary for selecting 
interactions with experimental evidence from the large set of ‘common knowledge’ (but often 
not sufficiently verified) interactions used in many reviews (Cusick et al., 2009). All 
interactions in SignaLink are directed. For most of the interacting protein pairs in SignaLink 
the unidirectional (only AB) and for a few pairs it is bidirectional (both AB and BA). 
The interaction type descriptors ‘direct’ and ‘indirect’ indicate whether there is biochemical 
(direct) or other type of evidence (indirect), respectively. For details see the next section. 
 
Manual curation process of SignaLink 
 
All pathways of the three species were compiled (i.e., manually curated) separately. 
SignaLink contains no interologs (Cusick et al., 2009; Yu et al., 2004). For each pathway, we 
performed the following three main steps. First, we searched for pathway-specific review 
articles and databases. Next, we added to each pathway the signaling proteins listed as the 
members of that pathway in the review papers. Finally, we searched again for additional 
signaling interactions of the listed pathway proteins. 
Proteins 
Data on proteins were collected as follows. 
• ORFs and Ensembl protein IDs from species-specific databases: WormBase (version 
191) (Rogers et al., 2008), FlyBase (version 2008.6) (Drysdale, 2008), and Ensembl 
(version 49) (Flicek et al., 2008). 
• UniProt IDs from UniProt (version 87) (Boutet et al., 2007). If more than one UniProt 
ID was available for the same protein, then the ID(s) of the protein(s) with the longest 
amino acid sequence was (were) used. 
• Protein name synonyms were listed from review papers, e.g., Ref. (Kyriakis and 
Avruch, 2001), and the “synonym” field of the iHOP database (May 2008 version) 
(Fernandez et al., 2007). 
• For protein ID conversions we used also PICR, the Protein Identifier Cross-Reference 
Service (Cote et al., 2007) and the Synergizer (Berriz and Roth, 2008). 
• For each protein we listed its orthologs in the other two species with the help of the 
ortholog clusters of the InParanoid database (version 6.1) (Berglund et al., 2008). 
Consider an InParanoid cluster containing protein PA from species A and proteins PB,1 
and PB,2 from species B. From the PB proteins in the cluster we included into 
SignaLink only those with an InParalog score equal to or above 0.3. 
• When inserting a protein into SignaLink we assigned it to one pathway and – within 
that pathway – to one pathway region (e.g., EGF/MAPK core, TGF non-core, or NHR 
core). Later further pathways and pathway regions were added for this protein, if 
necessary. 
o We marked a protein a ‘core’ component of a pathway, if it is essential for 
transmitting the signal of its pathway and has at least one of the pathway’s 
biochemical characteristics, e.g., ‘Ser/Tyr-kinase activity’. 
o ‘Non-core’ (same as ‘peripheral’) indicates that the protein does not belong to 
the core of the pathway, but it modulates the pathway’s core proteins. 
• We determined the pathway section(s) of each protein separately, e.g., ligand or 
receptor. A maximum of two sections per protein were allowed. 
o The pathway position ligand indicates that the protein starts the signal of its 
pathway. 
o A receptor is the immediate receiver of this signal. 
o A mediator is a member of the pathway mediating the signal from the 
receptors towards transcription factors. 
o A co-factor modulates the function of any other protein. Note that co-factors 
are often in the peripheral (non-core) region of their pathways. 
o Transcription factor: (i) transmits the signal received from its pathway 
towards another transcription factor (TF) protein, or (ii) forms a complex with 
other TF proteins, or (iii) binds to a specific promoter region on the DNA. 
o Other: non-signaling proteins with the roles of cellular motion, transport, and 
membrane anchoring. In the worm, the fly, and humans SignaLink contains 14, 
10, and 13 proteins, respectively annotated with the pathway position “other”. 
Out of these proteins 3, 1, and 5, respectively are co-factors at the same time 
too, and the remaining 11, 9, and 8 proteins have no additional pathway 
position, only “other”. In summary, in SignaLink the pathway position “other” 
is used rarely, and it appears in combination with co-factor only. 
o Unknown: the position of this signaling protein in its pathway is not known. 
• After compiling the lists of proteins and signaling interactions we performed two 
further steps: 
o We went through the list of proteins again and for each protein, P, we listed all 
those interacting proteins, R, for which SignaLink contains a PR directed 
interaction. We added to the list of pathway memberships of P all pathways of 
each of these (R) proteins. 
o For each signaling protein in one species (A) we listed its orthologs from the 
other two species (B, C). For each of these orthologs we checked whether it 
has been found to interact with signaling proteins already listed in SignaLink 
(for species B or C). If yes, then we inserted the ortholog into SignaLink too. 
Interactions 
We used the following rules for collecting data on interactions. 
• We collected the signaling interactions of a protein from primary research articles 
listed in 
o review papers, 
o species-specific databases (FlyBase, WormBase) and UniProt, 
o iHOP, ChiliBot (Chen and Sharp, 2004), and PubMed search results. 
• Details: 
o Each interaction inserted into SignaLink had to be directed. 
o We made an effort to find the earliest possible experimental article describing 
the interaction. 
o For all review papers and approximately 70% of all primary experimental 
articles, we examined not only the abstract, but also the main text. 
o In SignaLink the experimental evidence for a signaling interaction between the 
two involved proteins is either direct or indirect:  
 Direct experimental evidence. There is published biochemical evidence 
for the signaling interaction between the two proteins.  
 Indirect experimental evidence. There is no direct biochemical evidence 
for an interaction, however, published experimental results suggest that 
the interaction is very likely possible. Evidence types accepted here are 
(1) changes in mRNA/protein levels, enzyme activities, concentrations 
of the products of catalyzed reactions, and (2) docking domain 
structures. 
o The effect of an interaction can be activating or inhibitory. For interactions 
with indirect evidence, ++ and -- mean activating, while +- and -+ mean 
inhibitory interaction. A unidirectional interaction (A and B interact as either 
AB or BA) has only one type of effect, but for the few bidirectional 
interactions (AB and BA are both present) more than one type of effect is 
possible between the two proteins. 
o Two signaling interactions between the same two proteins in opposing 
directions are listed separately in SignaLink. 
 
Pathways and proteins included into and excluded from SignaLink 
Signal transduction – briefly summarized – is the transmission of extracellular signals towards 
the nucleus. Based on this definition some protein families, pathways, and cellular systems 
were fully or partially excluded from SignaLink. 
 
Based on the summary of Gerhart (Gerhart, 1999) Pires da Silva and Sommer selected (Pires-
daSilva and Sommer, 2003) seven signaling pathways that are continuously active during 
development, have an essential role after the developmental processes, and are conserved in 
metazoans. We selected the same seven pathways and separated the RTK pathway group to 
EGF/MAPK and Ins/IGF. 
 
Several further signaling pathways used by Gerhart (for example, the integrin pathway or the 
apoptosis pathway), are active only occasionally (not continuously) and contribute mainly to 
adult physiology. These were excluded by Pires da Silva and Sommer. We excluded these 
pathways from SignaLink too. In addition to their late activity, the excluded pathways are 
often controlled by input signals that are not extracellular. Examples are the TOR and 
apoptosis pathways, some immune pathways (e.g., the NF-kB pathway), and cell cycle-related 
pathways such as the p53 system. 
 
For an additional protein to be included into SignaLink during the manual curation process, 
we required that (1) it has an experimentally verified role in one of the eight curated pathways 
or (2) it has a signaling interaction with an already listed SignaLink protein. 
 
The following cellular systems perform tasks other than signal transduction, thus only those 
of their proteins are present in SignaLink that have a direct connection to signaling proteins: 
• Clathrin- and non-clathrin-mediated endocytosis 
• Nuclear import/export system 
• Chromatin remodelling 
• The ubiquitin system 
 
Interactions between transcription factors (TFs) are mostly well-separated from signal 
transduction (ST) due to their different time scale, mechanisms, and cellular location (Papin et 
al., 2005). Thus, most TF-TF interactions have been omitted from SignaLink. Note that signal 
transduction pathways end on TFs, thus, many proteins are contained by both the ST system 
and the transcription regulation system. We stopped at the first TF of a pathway and did not 
insert its neighbors into SignaLink. If we found that several TFs directly interact with non-TF 
signaling proteins and these TFs interact themselves, then we inserted these TF-TF 
interactions into SignaLink too (e.g., between STAT3 and SMAD3). However, the co-factors 
of the NHR pathway were excluded from SignaLink, because they are members of the TF 
network and not the ST system. 
 
From the following protein families only those members have been included into SignaLink 
for which we could identify an experimentally verified role in at least one of the eight selected 
signaling pathways or an interaction with a SignaLink protein: 
• Heterotrimeric G proteins, 
• Non-receptor tyrosine kinases, 
• Receptor tyrosine kinases (RTK). 
 
From the 58 currently known RTK receptors SignaLink contains only 4 EGF and 4 IGF 
receptors (4 EGFR, 2 IGFR, IRR, and INSR) for the following reasons. 
• From the RTK pathway group, EGF/MAPK and IGF/INS are two pathways with 
sufficiently large sizes for comparisons. 
• Inserting all 58 RTK receptors and associated proteins (approximately 3-4 ligands and 
mediators per receptor) would merge the currently largest pathway, EGF/MAPK, with 
Ins/IGF, resulting in a single pathway significantly larger than all other pathways (Hh, 
JAK/STAT, NHR, Notch, TGF, and WNT) combined. Thus, inserting all RTK 
receptors and associated proteins would strongly reduce the usability of pathway 
comparisons. 
• In experimental work EGF and IGF receptors are often discussed separately. They are 
considered to be the two most important and representative receptor groups of the 
RTK family. Within the RTK pathway system EGF and IGF receptors are two of the 
most frequently researched receptor groups and they have clearly different functional 
roles. 
 
Note that despite their clearly different roles, the downstream effects of the two receptor 
groups (EGF and IGF) do have similarities: IGF receptors can also forward signals to the 
MAPK section of the EGF/MAPK pathway (Robinson et al., 2000). 
Curation process: Example 
As an example we discuss here the human Notch pathway and one of its components, the 
human NOTCH1 protein. 
• According to pathway-based reviews (Baron, 2003), in humans there are 4 Notch 
family member proteins: NOTCH1, NOTCH2, NOTCH3, and NOTCH4. 
• Notch proteins have a specific role in transmitting signals (Weinmaster, 1997). 
• The ligands and transcription factors between which Notch proteins transmit signals as 
well as several further proteins tuning the functions of Notch proteins are known 
(Bray, 2006). 
 
Protein data 
• Most databases and review papers do not differentiate between splice variants. For the 
human NOTCH1 protein Ensembl (Flicek et al., 2008) contains two splice variants: 
ENSP00000277541 and ENSP00000360765. From these two the InParanoid database 
(Berglund et al., 2008) contains only the first, ENSP00000277541, therefore, we 
inserted into SignaLink only this splice variant. For proteins that have more than one 
splice variant, but none of them is present in the InParanoid database, we inserted into 
SignaLink the splice variant that has a primary UniProt accession (AC), as listed by 
Ensembl version 49. 
• From Ensembl we included into SignaLink the UniProt accession(s) of the protein and 
from UniProt we used the following data fields: the protein’s description, the protein 
reference – if it contained interaction data, – and the protein’s cellular component. In 
addition, data from the protein's description and interaction fields were manually 
tested in the primary publications for further information. 
• According to Ref. (Ilagan and Kopan, 2007), NOTCH1 is a core protein of its pathway 
and it functions as a receptor, mediator, or transcription factor. However, when in the 
Notch pathway, NOTCH1 functions either a receptor or a transcription factor, thus, we 
have included into SignaLink only these two pathway sections for NOTCH1. 
• To make SignaLink as complete as possible, we searched for orthologs of the human 
NOTCH1 protein. Orthologs without known signaling interactions became predicted 
pathway proteins in SignaLink. 
• From the InParanoid database we identified the C. elegans and D. melanogaster 
orthologs of the human NOTCH1 protein (ENSP00000277541). (In several cases we 
searched by both the UniProt and Ensembl protein IDs in InParanoid to find the 
protein.) Interestingly, the human NOTCH1 has two orthologs in worm (LIN-12 and 
GLP-1), but only one ortholog in fly (the protein N). We inserted all three orthologs 
into SignaLink. We listed the species-specific protein IDs and the UniProt ACs of the 
orthologs from WormBase and FlyBase. 
• For ligands and transcription factors interacting with NOTCH1 we followed the same 
steps. 
 
Interactions 
• We listed articles describing signaling interactions between NOTCH1 and other 
proteins by browsing through the references of the above mentioned review papers 
and by using the search engines iHOP (Fernandez et al., 2007) and ChiliBot (Chen and 
Sharp, 2004). The search engine iHOP allows the user to search for all abstracts with 
interactions containing NOTCH1. With ChiliBot the interactions between two selected 
proteins can be directly searched for. 
• Consider, for example, the interaction between NOTCH1 and TACE/ADAM17. This 
interaction is described in the experimental article (Brou et al., 2000). After reading 
the article we found that it describes (i) a putative cleavage site for TACE on 
NOTCH1 and (ii) a correlation between the in vitro enzymatic activity of TACE and 
the activity of NOTCH1. Thus, this article provides evidence for the activation of 
NOTCH1 by TACE.  
• In addition, we searched directly for interactions between the orthologs of TACE and 
NOTCH1 in the other two species. 
Comparing the approach of SignaLink with other approaches 
Signaling pathways are the building blocks of signaling networks, however, their definition is 
not yet standardised. Thus, currently used definitions of signaling pathways are based on a 
variety of functional, structural, and cell specific classifications (Bader et al., 2006). As a 
consequence of this, more than one definition is in use for the system-level examination of 
signaling pathways. For example, the definition of cross-talks has not yet been standardised. 
 
Most of these approaches have a specific purpose, e.g., the characterisation of cell fate signals 
(Tseng and Dustin, 2002), the analysis of selected cell types (Grunwald and Klein, 2002) or 
selected pathways (Fuerer et al., 2008). Supplementary Table 2 lists several approaches to 
cross-talk analysis in the increasing order of the complexity of the examined system. The 
table starts with general cross-talk reviews of one selected pathway to intercellular cross-talk 
studies. While previous studies compared and discussed the cooperation of pathway pairs at 
most (Wang et al., 2009a; Nusse, 2003), SignaLink allows the user to perform both pathway-
specific and system-level analyses for all eight pathways, with an emphasis on cross-talk. 
 
Focus of the analysis Reference 
Cross-talks of  
    in healthy cell types 
(Guo and Wang, 2009) 
(Hurlbut et al., 2007) 
    one pathway in stem cells (Katoh and Katoh, 2007) 
    two pathways (Borisov et al., 2009; Wang et al., 
2009a) 
    selected pathways in one tissue type (Natarajan et al., 2006) 
    many pathways in one tissue type (Sternberg, 2005) 
    many pathways in stem cells (Blank et al., 2008) 
    many pathways in one organ (Yan et al., 2004) 
Intercellular cross-talk 
    between two pathways in one organ 
(Boswell et al., 2008) 
Supplementary Table 2. Approaches to signaling cross-talk analysis in metazoans. 
 
Databases usually agree on the ‘cores’ (backbones) of signaling pathways, but peripheries are 
often captured very differently. To circumvent the ambiguity of pathway boundaries, Gerstein 
and colleagues have embedded pathway ‘cores’ into the large-scale network of all known 
PPIs (Lu et al., 2007). Lu et. al. also point out that the individual signaling databases of 
pathways are often assembled by several professionals applying different collection criteria 
and thus, it can be misleading to merge such pathway collections into a single database and 
perform cross-talk analyzes on them. The features setting SignaLink clearly apart from other 
pathway databases are shown in Supplementary Table 3. 
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Comparing the human signaling pathways of KEGG, Reactome, NetPath, and 
SignaLink 
 
Manual curation projects are (i) inherently error-prone (Cusick et al., 2009) and (ii) require 
specific goals that define their curation criteria. Comparisons between both the curation 
protocols (Rzhetsky et al., 2009) and the resulting databases are essential. In the current paper 
we publish a database and some of its possible applications. Therefore, not the curation 
process, but the database itself – SignaLink – should be compared to others. 
 
The number of databases collecting signaling interactions is constantly growing (Bader et al., 
2006). However, many of these databases are proprietary, list fewer than 200 molecules, or 
only selected types of pathway components (e.g., protein kinases). Even among the few 
databases passing these criteria – free for academic use, more than 200 molecules, contains all 
pathway component types – there are currently no gold standards of signal transduction 
pathways compiled with similar purposes and methods as SignaLink. Thus, SignaLink as a 
whole cannot be validated at this moment. 
 
 
Due to the absence of appropriate gold standards we compared the human signaling pathways 
of SignaLink with those from 3 widely used pathway databases: KEGG, Reactome, and 
NetPath. For reference we compared the human signaling pathways of these three databases 
to each other too. Except where explicitly stated, for the comparisons we mapped all protein 
IDs to UniProt primary accessions (e.g., P42224). For the tables and text below we converted  
UniProt primary accessions to HGNC symbols (e.g., we mapped P42224 to STAT1). 
 
As discussed below, there are several important differences between these databases: 
− Availability of a detailed description of the curation method 
− Data sources (none, research articles, or only reviews) 
− Entities connected by the interactions differ: pathways, proteins, ortholog groups, protein 
families, etc. 
− Usage of protein isoform names 
− Protein complexes allowed or not as a source of binary interactions 
− Additional attributes of the interactions (e.g., directed/undirected) 
− Type of protein identifier used (UniProt AC, RefSeq ID, etc.) 
− Number of cross-talks 
− Database-specific (overrepresented) molecular functions 
 
We believe that a comprehensive analysis of these differences is essential when deciding 
about which database should be used for a particular application. Below we compare the 
curation methods and contents (proteins and interactions) of the four databases. First through 
pairwise comparisons between the databases, e.g., KEGG-SignaLink or Reactome-SignaLink, 
and then in a summary encompassing all four databases. 
 KEGG BIOCARTA pSTIING REACTOME Science 
Signaling – 
STKE 
NCI Nature – 
Pathway 
Interaction 
Database 
HPRD-
NetPath 
SignaLink 
Number of species Many but most 
networks are 
based on 
humans 
Humans and mouse Humans, rat, 
mouse, fly, worm, 
and yeast 
Many Many Only humans Only humans 3  
(C. elegans, 
Drosophila, 
Humans) 
Source of pathway 
components 
Subjective 
manual curation 
from the 
literature  
Subjective manual 
curation from the 
literature 
Subjective manual 
curation from the 
literature 
Reaction based 
manual curation 
Subjective manual 
curation from the 
literature 
Subjective manual 
curation from the 
literature 
Subjective manual 
curation from 
HPRD 
Many pathway 
reviews, further 
manual curation 
Source of interactions Only reviews Mostly reviews PubMed ID listed 
for each interaction 
PubMed ID listed 
for each interaction 
PubMed ID listed 
for some 
interactions (not all) 
PubMed ID listed 
for each interaction 
PubMed ID and 
cited reaction 
details listed for 
each interaction 
PubMed ID listed 
for each interaction 
Type of interactions Directed Directed Directed Directed Directed Directed Undirected Directed 
Number of signaling 
pathways (only 
differences from 
SignaLink are shown)  
10 
(no NHR) 
Many  12 
(no WNT, TGF, 
Notch, IGF, Hh, 
NHR ) 
10 but not for every 
species 
(no Hh, NHR, 
JAK/STAT) 
49 canonical, 32 
specific 
(no NHR) 
82 
(no NHR, 
JAK/STAT) 
20 
(no WNT, IGF, 
NHR, JAK/STAT) 
8 
(EGF/MAPK, 
WNT, TGF, Notch, 
IGF, Hh, NHR, 
JAK/STAT) 
Definition of 
pathways 
Not defined Not defined Immune pathways Not defined; 
uniform curation 
rules 
Not defined Not defined Cancer or immune 
pathways 
Biochemically 
based, important in 
development; 
uniform curation 
rules 
Pathways with (i) 
uniform curation 
criteria and (ii) 
readily available for 
cross-talk analysis 
Not possible Not possible Possible Possible, but 
no global 
pathway view 
or common 
platform  
Not possible Not possible Not possible Possible 
Availability 
(cost, data structure, 
website) 
Free, 
web based, 
www.genome.jp
/kegg 
 
Free, but only 
diagram image and 
protein list, 
www.biocarta.com 
 
Free, 
web based, 
pstiing.licr.org 
 
Free, 
SQL dump, 
www.reactome.org 
 
Free after 
registration, 
Web based, SBML 
upon request, 
stke.sciencemag.org 
Free, 
PID XML and 
BioPAX, 
pid.nci.nih.gov 
 
Free,  
in many network 
formats 
www.netpath.org 
 
Free,  
SQL dump,  
SBML 
signalink.org 
 
Supplementary Table 3. Comparison of SignaLink with other manually curated signaling databases.  
KEGG and SignaLink: A comparison of isoforms and the definition of 
interacting entities 
 
Listing signaling interactions from KEGG pathway files 
 
The Kyoto Encyclopedia of Genes and Genomes (Ogata et al., 1999) contains a large number 
of pathways, among them signal transduction and endocrine pathways. Out of the 8 pathways 
curated in SignaLink 7 are listed in KEGG: MAPK, WNT, Notch, Hedgehog, TGF-beta, Jak-
STAT, and Insulin. 
 
The pathways of KEGG contain seven types of entries: compound, group, map, ortholog, 
gene, enzyme, and other. From these we used only orthologs and their interactions. In KEGG 
each ‘ortholog’ entry is a group of proteins, which may contain more than one human protein. 
In KEGG an interaction connects two entries, e.g., two ortholog groups, and – to the best of 
our knowledge – an interaction between two ortholog groups does not contain information 
about which proteins from the two ortholog groups are the actual interactors.  
 
For each of the above mentioned seven pathways we first downloaded the corresponding PSI-
MI formatted xml pathway file from ftp://ftp.genome.jp/pub/kegg/pathway/organisms/hsa in 
April 2009. These seven KEGG pathways contain four types of entries (usage in brackets): 
ortholog (373), map (40), group (15), and compound (11). We discarded ‘map’ (a linked 
pathway map, which denotes an entire pathway) and ‘compound’ (a chemical compound 
including, for example, glycan) entries, and retained ‘ortholog’ and ‘group’ (a complex of 
gene products, mostly a protein complex) entries. 
 
In the seven downloaded xml formatted pathway files the name of an ’ortholog’ type entry 
contained one or more ‘KEGG ortholog set (ko)’. For example, in the file 04330_Notch.xml 
the type of entry number 3 is ‘ortholog’ and its name is a space-separated list containing three 
KEGG ortholog sets: “ko:K04505 ko:K04522 ko:K06060”. Each of these three KEGG 
ortholog sets contains one human protein. We used the file hsa_ko.list to map these KEGG 
ortholog set identifiers to KEGG’s Homo sapiens protein numbers. In the example we 
mapped  ko:K04505 to hsa:5663, ko:04522 to hsa:5664, and we could not map ko:06060 (this 
ID was discarded). Next, we mapped KEGG’s Homo sapiens protein numbers to UniProt 
accessions with the file hsa_uniprot.list, in the example for hsa:5663 two UniProt accessions 
were listed (B2R6D3 and P49768), we mapped hsa:5663 to P49768 and similarly, we mapped 
hsa:5664 to the second of the two listed UniProt accessions (B1AP21, P49810). Note that in 
both cases, the first UniProt AC is from TrEMBL, while the second is from Swiss-Prot. By 
checking a few examples in the file hsa_uniprot.list we concluded that if for a KEGG Homo 
sapiens protein number more than one UniProt accession (AC) is listed and at least one of 
these ACs is from Swiss-Prot, then the last AC is from Swiss-Prot. Thus, to use a more 
reliable protein AC – one from Swiss-Prot, if possible – we used always the last AC. 
 
The ‘group’ entries in the downloaded xml files of KEGG pathways contain components 
which are themselves entries from the same xml file. We replaced each ‘group’ entry with the 
list of its ‘ortholog’ components and we replaced each of these ortholog components with the 
list of the UniProt accessions found as explained above. In summary each pathway entry that 
we kept for the analysis contained one or more protein name (in UniProt AC format). 
 
KEGG pathways list directed interactions between entries. Each of the entries we used 
contained one or more human protein. We used only those interactions where the two 
connected entries were both among the ortholog or group entries selected above. For the 
seven pathways this selected list of directed interactions gave 285 nodes (protein groups) and 
210 directed links between these groups. The total number of proteins in these groups was 
429. 
 
 
Constructing the network of signaling interactions from KEGG pathways 
 
In the previous subsection we explained how we listed the directed signaling interactions 
connecting groups of human proteins from the KEGG pathways MAPK (we compare it to the 
EGF/MAPK pathway of SignaLink), WNT, Notch, Hedgehog, TGF-beta, JAK/STAT, and 
Insulin. We used two alternatives to construct a network of directed signaling interactions 
from these data. We used the ‘matrix’ and ‘spoke’ methods, which are frequently applied for 
constructing binary protein-protein interaction lists from protein complex data (Orchard et al., 
2007). 
 
We called the two groups of proteins connected in KEGG by a directed signaling interaction a 
source group and a target group. For the first KEGG signaling network (‘KEGG matrix’) we 
connected with a directed signaling interaction each protein of the source group with each 
protein of the target group. For the second KEGG signaling network (‘KEGG spoke’) we 
selected one protein from the source group and one protein from the target group and added a 
directed signaling interaction only between these two proteins. Both protein groups contained 
UniProt primary accessions (allowing both Swiss-Prot and TrEMBL proteins). We picked the 
selected protein from a group by (i) putting accessions into alphabetical order and then (ii) 
picking either the first Swiss-Prot accession from the list or – if only accessions from 
TrEMBL were listed – the last accession. 
 
 
Comparing the human signaling pathways of KEGG and SignaLink 
 
To compare KEGG with SignaLink, we considered the ‘KEGG matrix’ and ‘KEGG spoke’ 
networks (see the previous section) constructed from the KEGG pathways MAPK, WNT, 
Notch, Hedgehog, TGF-beta, JAK/STAT, and Insulin. Note in Supplementary Table 4 that the 
number of ‘SignaLink only’ proteins is well above the number of KEGG spoke ‘KEGG only’ 
proteins. Only in the ‘KEGG matrix’ network – which very likely contains many false 
positive links – is the number of signaling interactions comparable to that of SignaLink. 
 
For the comparisons in Supplementary Table 4 we mapped first each protein name (both in 
KEGG and SignaLink) to a UniProt primary accession (AC). The comparisons labelled “all 
isoforms names separately” were performed on these lists. Next we mapped each UniProt 
primary AC to the HGNC gene name listed in UniProt or – if there was no HGNC name – the 
truncated ID (the ID minus the “_HUMAN” tag). Finally, in these name lists we removed 
from the name of each protein any of the following patterns, if they followed a number: (i) a 
single letter (for example, WNT10A was replaced with WNT10), (ii) a letter and a number 
(e.g., CSNK2A1 was replaced with CSNK2), and (iii) a letter, a number and a letter (e.g., 
CSNK1A1L was replaced with CSNK1). In addition to these rules MAPK protein names (i.e., 
names starting with “MAPK”) were not changed (protein names starting with ”MAP” 
followed by zero or more numbers, a ”K” and then optional further characters were 
considered to be MAPK protein names). We performed the comparisons labeled “merged 
isoform names” (M) on these final name lists. 
 
 
Pathway 
Proteins and interactions 
M: isoform names merged, S: all isoforms listed separately 
 only in KEGG intersection: 
both in KEGG 
‘matrix’ and 
SignaLink 
only in 
SignaLink  KEGG ‘matrix’ 
KEGG 
‘spoke’ 
 M (S) M (S) M (S) M (S) 
          
Pr
ot
ei
ns
 
EGF/MAPK 85 (101) 57 (59) 63 (63) 98 (99) 
Hh 16 (20) 4 (5) 14 (13) 25 (26) 
IGF 65 (65) 51 (51) 9 (9) 26 (28) 
JAK/STAT 24 (24) 14 (14) 54 (55) 55 (66) 
Notch 10 (10) 8 (8) 14 (14) 25 (25) 
TGF 26 (26) 19 (19) 19 (19) 64 (67) 
WNT 52 (62) 40 (43) 32 (26) 41 (49) 
         Total 
all proteins 196 (224) 137 (145) 210 (205) 252 (278) 
multi-pathway proteins 27 (34) 19 (19) 8 (7) 36 (36)  
         
In
te
r-
 
A
ct
io
ns
 Total 1332 (1411) 301 (307) 199 (191) 775 (799) 
Cross-talks 
(weighted number) 214.1 (199.8) 74.5 (71.5) 11.3 (10.3) 216.8 (214.9) 
Supplementary Table 4. Protein and interaction numbers in the seven signaling pathways curated by both 
KEGG and SignaLink. The label “only in KEGG” indicates proteins (or interactions) listed only in KEGG, 
“intersection” indicates proteins (or interactions) listed in the given pathway(s) of both databases, and “only in 
SignaLink” indicates names listed only in SignaLink. In KEGG each directed signaling interaction connects two 
groups of proteins (a source group and a target group). In the KEGG ‘matrix’ network for each directed 
interaction we added a directed link between each protein of the source group and each protein of the target 
group. In the KEGG ‘spoke’ network only one protein from the source group was connected with one protein 
from the target group. See the section “Analysis of cross-talk in each species” in “Supplementary Results” above 
for the definition of weighted link numbers and a detailed description. Pathways in which the removal of isoform 
names significantly reduces the number of proteins are highlighted with gray background. See text for the 
discussion of this table.  
 
Removing isoform names (i.e., merging name variants) has a significant effect on the lists of 
proteins in several pathways. We found that KEGG contains a significant number of isoforms 
in both the MAPK and WNT pathways, and SignaLink contains some in the WNT pathway. 
In addition, both databases contain many – but not the same – isoforms in the JAK/STAT 
pathway. Observe also in the ‘M’ columns (where isoform names are merged) of 
Supplementary Table 4 that the KEGG ‘matrix’ data set contains significantly more proteins 
than SignaLink in the IGF pathway (74 vs. 35) and notably more proteins (84 vs. 73) in the 
WNT pathway, while all other pathways are more populous in SignaLink. In total SignaLink 
and the KEGG matrix data set have similar numbers of proteins and almost the same 
(weighted) cross-talk numbers. However, the KEGG matrix data set – as all networks 
prepared with the matrix method – is very likely to contain many false positive interactions. 
Thus, in our opinion SignaLink contains significantly more biologically meaningful signaling 
interactions, including cross-talks, than KEGG. 
 
 
Conclusions for the comparison between KEGG and SignaLink 
 
Considering the seven signaling pathways curated in both databases, we found the following 
differences between KEGG and SignaLink: 
• With the most permissive approach – KEGG ‘matrix’ with isoforms – the selected 7 
pathways of KEGG have 20% fewer proteins than the same 7 pathways in SignaLink 
(429 vs. 483 proteins). However, with the same approach KEGG has 50% more 
(undirected) interactions (1 502 vs. 990). This large number of links probably includes 
many that were introduced only by the ‘matrix’ method, and do not exist in reality. 
• Although in SignaLink the weighted number of cross-talks is higher, KEGG has 
significantly more (50%) interactions between fewer (20%) proteins. This is mainly 
due to the higher number of interactions within the pathways of KEGG. 
• Several pathways contain large numbers of isoform names. After merging isoform 
names, the total number of proteins contained exclusively by either of the two 
databases decreases, while the total number of proteins contained by both databases 
increases. 
 
Reactome and SignaLink: Complexes and database-specific molecular functions 
 
We downloaded the files uniprot_2_pathways.stid.txt and homo_sapiens.interactions.txt in 
April 2009 from the web directory http://www.reactome.org/download/current of Reactome 
(Joshi-Tope et al., 2005). There are five signaling pathways that have been curated both in 
Reactome and in SignaLink: EGF (EGRF in Reactome and EGF/MAPK in SignaLink), 
IGF/Ins, Notch, TGF, and WNT. 
 
From the first of the two data files (uniprot_2_pathways.stid.txt) we extracted the protein lists 
of the EGFR pathway (“Signaling by EGFR”, to be compared to the EGF/MAPK pathway of 
SignaLink), the IGF/Ins pathway (“Signaling by Insulin receptor”), the Notch pathway 
(“Signaling by Notch”), the TGF pathway (“Signaling by TGF beta” merged with “Signaling 
by BMP”), and the WNT pathway (“Signaling by Wnt”). Next we converted protein 
identifiers to UniProt primary accessions. From the second of the two data files 
(homo_sapiens.interactions.txt) we listed all interactions between the proteins of the five 
pathways. Reactome lists binary interactions classified into four interaction types: 
‘neighbouring_reaction’ (528 of them connect proteins of the five selected pathways), 
‘reaction’ (535), ‘indirect_complex’ (349), and ‘direct_complex’ (950). 
 
SignaLink contains binary protein-protein interactions, but no binary associations between 
two proteins inferred from the membership of the two proteins in the same protein complex. 
Reactome contains both. In Reactome ‘direct_complex’ and ‘indirect_complex’ are the labels 
indicating binary associations between two proteins inferred from the membership of the two 
proteins in the same protein complex. For a mathematically and biologically meaningful 
comparison of Reactome and SignaLink only true binary protein-protein interactions should 
be used. In Supplementary Table 5 this comparison is marked ‘N’ (Binary interactions of 
Reactome inferred from membership in the same protein complex are excluded). As 
Reactome interaction data are often used in the literature without a distinction between 
Reactome data types, we have also performed the comparison by including ‘complex’ 
associations: in Supplementary Table 5 ‘C’ indicates that in this comparison the Reactome 
data set includes binary protein-protein associations derived from the membership of the two 
proteins in the same protein complex. 
 Pathway 
Proteins and interactions 
N: Reactome without complexes 
C: Reactome with complexes 
only in 
Reactome 
both in 
Reactome and 
SignaLink 
only in 
SignaLink 
N (C) N (C)   
      
Pr
ot
ei
ns
 
EGF/MAPK 28 (28) 16 (16) 146 
IGF 32 (32) 7 (7) 30 
Notch 2 (2) 14 (14) 25 
TGF 10 (11) 19 (19) 67 
WNT 5 (53) 4 (5) 70 
    Total      
all proteins 56 (105) 64 (65) 283 
multi-pathway proteins  6 (15) 0 (2) 39 
 
Inter-
actions 
Total      
all interactions 622 (1454) 67 (73) 615 
cross-talks (weighted sum)  39.3 (39.3) 0 (0) 216.5 
Supplementary Table 5. Statistics of the five signaling pathways curated in both Reactome and SignaLink. 
Observe that (i) protein lists significantly differ and (ii) in each pathway SignaLink contains a larger number of 
proteins. Note that the removal of ‘complex’ interactions from Reactome reduces from 58 to 9 the number of its 
WNT pathway proteins that have at least one interaction with another WNT pathway protein. On the other hand 
the removal of ‘complex’ interactions leaves the list of cross-talks in Reactome’s selected five pathways 
unchanged. Thus, ‘complex’ interactions in Reactome connect pairs of proteins within pathways, mostly within 
the WNT pathway. Note also that the the number of proteins contained by both databases is low. 
 
Supplementary Figure 2. The relative frequency of the usage of each GO Molecular Function term annotating 
the proteins of the five signaling pathways curated in both Reactome and SignaLink. The terms called 
“Reactome-specific” and “SignaLink-specific” are those terms that annotate at least three times as many proteins 
(compared to the total number of proteins) in one data set as in the other. 
 
 
 
GO Molecular Function term 
Number of proteins 
annotated with this term 
in Reactome in SignaLink 
   Reactome-specific terms (at least 3 times more frequently used in the Reactome subset) 
GO:0008233 peptidase activity  25 5 
GO:0004298 threonine-type endopeptidase activity  17 - 
GO:0016887 ATPase activity  6 - 
GO:0043560 insulin receptor substrate binding  5 2 
GO:0008601 protein phosphatase type 2A regulator activity 5 2 
etc.   
   SignaLink-specific terms (at least 3 times more frequently used in the Reactome subset) 
GO:0008083 growth factor activity 5 31 
GO:0004713 protein tyrosine kinase activity 2 18 
GO:0043565 sequence-specific DNA binding 1 21 
GO:0004722 protein serine/threonine phosphatase activity 1 8 
GO:0004708 MAP kinase kinase activity 1 10 
GO:0004707 MAP kinase activity 1 10 
etc.   
   Non-specific terms (most frequently used non-specific terms) 
GO:0005515 protein binding 107 186 
GO:0000166 nucleotide binding 40 104 
GO:0005524 ATP binding 34 97 
GO:0016740 transferase activity 24 93 
GO:0005509 calcium ion binding 17 13 
GO:0004674 protein serine/threonine kinase activity 13 74 
etc.   
Supplementary Table 6. The usage of GO Molecular Function terms annotating the proteins of the five 
signaling pathways curated in both Reactome and SignaLink. The total number of proteins is 170 in the 
Reactome subset and 348 in the SignaLink subset. 
 
In the five compared pathways both the protein and interaction lists of Reactome and 
SignaLink significantly differ (Supplementary Table 5). To quantify the possible reasons for 
this difference we first listed all Gene Ontology (GO) Molecular Function terms (Harris et al., 
2004) that annotate at least one protein in Reactome or SignaLink. For each of these terms we 
counted the number of proteins it annotates in Reactome and the number of proteins it 
annotates in SignaLink.  Supplementary Figure 2 and Supplementary Table 6 show these two 
numbers for each GO Molecular Function term and the two sets of terms typical for Reactome 
and SignaLink. 
 
 
Conclusions for the comparison between Reactome and SignaLink 
 
In summary, we found the following main differences between the five signaling pathways 
curated in both Reactome and SignaLink: 
• The selected five pathways of SignaLink contain more than twice as many proteins 
(348) as the same pathways in Reactome (170). After removing interactions labelled 
‘direct_complex’ and ‘indirect_complex’ from Reactome, this difference becomes 
even larger: the five selected pathways of Reactome will contain only 56 such proteins 
that have at least one signaling interaction with another signaling protein in these five 
pathways. 
• Without complexes Reactome has almost the same number of interactions in the five 
pathways as SignaLink (689 vs. 682). However, SignaLink has almost three times as 
many cross-talks (226 vs. 79). After adding Reactome’s complex interactions 
(‘direct_complex’ and ‘indirect_complex’) the number of its within-pathway 
interactions increases more than twofold (to 1527), however, the number of cross-talks 
is unchanged. Thus, the ‘complex’ interactions of Reactome (i.e., the binary signaling 
interactions inferred from the membership of two proteins in the same complex) are 
mostly within pathways. 
• In Reactome the WNT pathway is dominated by interactions inferred from the 
membership of two proteins in the same complex.  
• Several binding functions frequently occur in both databases. However when 
comparing the two databases to each other we found that proteolytic functions are 
more frequent in Reactome and kinases are more frequent in SignaLink. 
 
NetPath and SignaLink: Interactions, protein identifiers, cited papers, and 
curation approaches 
NetPath was originally published as a part of the Human Protein Reference Database 
(Keshava Prasad et al., 2009) and was recently published in a separate database article 
(Kandasamy et al., 2010). It contains human proteins and interactions grouped into 20 
pathways. In NetPath a protein is allowed to belong to more than one signaling pathway. 
There are 5 signaling pathways that are curated in both NetPath and SignaLink: EGFR1, 
Hedgehog, Notch, TGF beta Receptor, and WNT. The other 15 pathways in NetPath are 
specific for immune cells or cancers. 
 
For each interaction NetPath provides a list of interactors. To convert these interactions to a 
list of interacting pairs, we used the ‘matrix’ model (Bader and Hogue, 2002): each pair of 
human proteins appearing together in at least one interaction was listed as an interacting pair. 
We discarded self-interactions, i.e., interactions containing a protein interacting with itself. 
We note here that the number of human proteins in a NetPath interaction is typically two or 
three, thus, for the matrix model is a reasonably precise way to map the list of interactions 
(protein sets) to a list of interacting pairs. 
 
For each of the five pathways we have 
1. Downloaded pathway data in a single file from http://www.netpath.org/data/psimi_2, 
2. Selected the human proteins (by the taxonomy ID: 9606) in each interaction, 
3. Listed all human proteins of the pathway, 
4. Listed pairs of interacting proteins with the ‘matrix’ model, and 
5. Listed NetPath proteins with their RefSeq protein IDs, and mapped these later to 
UniProt primary accession (AC) identifiers. 
 
For the comparisons shown in Supplementary Tables 7 and 8 we considered the proteins of 
the five selected pathways of NetPath and all interactions between these proteins. We did the 
same in SignaLink. 
 
In Supplementary Table 8 we compare the lists of articles cited by the two databases for the 
five selected pathways. NetPath lists PubMed IDs (PMIDs) in each of its pathway files, e.g., 
at http://www.netpath.org/data/psimi_2/NetPath_10_PSIMI.xml for the EGFR1 pathway. 
From SignaLink we listed for each pathway (or the five pathways together) the PMIDs of 
those articles that provided experimental evidence for the interactions connecting two proteins 
that are both contained by the selected pathway (or pathway group). 
 
 Supplementary Table 7. Statistics of the five signaling pathways curated in both NetPath and SignaLink. For 
the comparison all protein names – RefSeq IDs from NetPath and UniProt accessions (AC) from SignaLink – 
have been converted to UniProt primary accessions. For the five signaling pathways NetPath and SignaLink list 
roughly the same number of proteins: 362 and 355, respectively. Altogether the two databases list 636 proteins 
for the five pathways, but only 81 protein names are listed in both cases. This large difference is in part due to 
the significant number of proteins in NetPath that have either not yet been verified fully with experiments and 
are listed in UniProt/TrEMBL (100 such proteins) or are not listed in UniProt at all (10 proteins). The number of 
cross-talks is much larger in SignaLink (weighted number: 171.1 vs. 59.8) and only a few of these cross-talks are 
present in both databases (weighted number: 1.5). Observe that in SignaLink the amount of proteins that belong 
to more than one pathway is more than twice as many as in NetPath. Note also that the low number of proteins 
contained by both NetPath and SignaLink makes the number of interactions contained by both databases also 
very small. 
 
 
Pathway 
Number of proteins or interactions listed 
for this pathway 
only in 
NetPath 
both in NetPath 
and SignaLink 
only in 
SignaLink 
EGF/MAPK 
    All proteins 
        Listed in UniProt/Swiss-Prot   
        Listed in UniProt/TrEMBL 
        Not found in UniProt 
    All interactions (undirected) 
115 
72 
42 
1 
141 
19 
19 
0 
0 
0 
143 
143 
0 
0 
351 
Hh 
    All proteins 
        Listed in UniProt/Swiss-Prot 
        Listed in UniProt/TrEMBL 
        Not found in UniProt 
    All interactions (undirected) 
 
5 
2 
2 
1 
10 
 
12 
12 
0 
0 
4 
 
27 
27 
0 
0 
53 
Notch 
    All proteins 
        Listed in UniProt/Swiss-Prot  
        Listed in UniProt/TrEMBL 
        Not found in UniProt 
    All interactions (undirected) 
 
42 
25 
16 
1 
38 
 
11 
11 
0 
0 
2 
 
28 
27 
0 
1 
58 
TGF 
    All proteins 
        Listed in UniProt/Swiss-Prot 
        Listed in UniProt/TrEMBL 
        Not found in UniProt 
   All interactions (undirected) 
 
103 
63 
36 
4 
186 
 
17 
17 
0 
0 
0 
 
69 
68 
1 
0 
188 
WNT 
    All proteins 
        Listed in UniProt/Swiss-Prot 
        Listed in UniProt/TrEMBL 
        Not found in UniProt 
    All interactions (undirected) 
 
61 
36 
20 
5 
84 
 
20 
20 
0 
0 
4 
 
55 
55 
0 
0 
94 
Five pathways together 
    All proteins 
        Listed in UniProt/Swiss-Prot 
        Listed in UniProt/TrEMBL 
        Not found in UniProt 
        Multi-pathway proteins           
    All interactions (undirected) 
    Cross-talks (weighted sum) 
 
         281 
171 
100 
10 
15 
446 
58.3 
 
81 
81 
0 
0 
2 
11 
1.5 
 
274 
273 
1 
0 
39 
690 
169.6 
 Pathway 
Number of papers cited for the 
interactions of this pathway 
only in 
NetPath 
both in NetPath 
and SignaLink 
only in 
SignaLink 
    EGF/MAPK 132 3 206 
Hh 9 5 23 
Notch 47 10 24 
TGF 95 18 74 
WNT 53 17 61 
    All 5 pathways  
all papers 327 61 337 
Supplementary Table 8. The number of articles cited for the interactions of the five signaling pathways 
(EGF/MAPK, Hedgehog, Notch, TGF, and WNT) that are curated in both NetPath and SignaLink. 
 
Conclusions for the comparison between NetPath and SignaLink 
 
We conclude that the major differences between the five signaling pathways curated in both 
NetPath and SignaLink are the following: 
• SignaLink contains more than two times as many multi-pathway proteins and nearly 
three times as many cross-talks as NetPath. 
•  NetPath – compared to SignaLink – contains a much higher number of proteins listed 
only in UniProt/TrEMBL, but not in UniProt/Swiss-Prot. Note that proteins listed in 
UniProt/TrEMBL have not yet been fully experimentally verified as known proteins. 
• The two databases (NetPath and SignaLink) were compiled with very different 
concepts in mind. We assume that NetPath was compiled using protein properties 
listed in UniProt (both Swiss-Prot and TrEMBL) and interactions in HPRD. As a 
contrast, SignaLink is review-based and its concept is to identify the functions of 
known proteins within their signaling pathways. This conceptual difference between 
NetPath and SignaLink may partly explain why the number of papers used for the 
compilation of both NetPath and SignaLink is low (see Supplementary Figure 8). 
• SignaLink contains directed binary signaling interactions, while NetPath lists groups 
of interacting signaling proteins.  
• SignaLink is available for three metazoan species, while NetPath is available only for 
humans. 
 
Pairwise comparisons between all four databases: Reactome, NetPath, KEGG, 
and SignaLink 
As shown in the previous sections the four compared databases list significantly different 
numbers of proteins for several signaling pathways. The following signaling pathways have 
been curated in all four databases: EGF/MAPK (MAPK, EGFR1), Notch, TGF, and WNT. In 
Supplementary Figure 3 we compare all four databases on one diagram using these four 
pathways. 
 
 
Supplementary Figure 3. Venn diagram comparing the four signaling pathways (EGF/MAPK, Notch, TGF, and 
WNT) curated in all four databases: Reactome, NetPath, KEGG, and SignaLink. Each section of the diagram 
shows the number of proteins in that set. The total number of proteins in the four pathways of each database is 
shown below the name of the corresponding database. Only proteins listed in UniProt/Swiss-Prot are included 
(proteins listed in UniProt/TrEMBL have been excluded from this comparison). Diagram layout from 
http://en.wikipedia.org/wiki/Venn_diagram. 
 
Comparing the lists of publications referenced in signaling pathway databases 
 
Database 
name 
Number of all pathways 
(signaling and other) 
Number of human 
pathways that have an 
equivalent in SignaLink 
Number of equivalent 
human pathways in 
SignaLink 
BioCarta 351 * 34  8 
KEGG 270 ** 7 7  
NCI 107 * 20 5  
NetPath 20 * 5 5  
pSTIING 38 * 10 3  
Reactome 997 * 5 5  
SignaLink 8 ** 8 8 
STKE 84 ** 35 8 
 
Supplementary Table 9a. Number of human pathways in cellular signaling databases. *Only human pathways. 
**A pathway available in more than one organism is counted as one pathway. 
 
 
 
 
 
 
 
 
Database 
name 
Total number of 
cited papers 
(signaling and 
other pathways)  
Number of cited papers for the 
signaling pathways available in 
SignaLink 
Number of cited 
papers 
Average number 
per pathway 
BioCarta* 1174 86 2 
KEGG 2388 73 10.4 
NCI* 1287 200 10 
NetPath* 1109 351 70.2 
pSTIING†,* n.a. n.a. n.a. 
Reactome 4491 166 33.2 
SignaLink‡ 941 941 42.8 
STKE† n.a. n.a. n.a. 
Supplementary Table 9b. Statistics of the publications cited in cellular signaling databases. Included are those 
publications that have been used for manual curation in the given pathway database and are available on its 
website either as a downloadable file or for viewing with a browser. Note that while Supplementary Table 8 
counts the publications cited for the interactions of a given pathway in SignaLink, in this table the numbers in 
the last column indicate the publications cited for pathway membership in SignaLink.*Only human pathways. 
†No online source of the list of publications used for curation could be identified (n.a.: not available). ‡To curate 
pathway membership and interactions SignaLink uses a total of 941 review and research articles while for 
curating pathway membership only review papers have been used. 
 
In Supplementary Table 9b we compare the numbers of publications cited by BioCarta, 
KEGG, NCI (NCI-Nature Pathway Interaction Database), NetPath, pSTIING, Reactome, and 
STKE (Signal Transduction Knowledge Environment, Database of Cell Signaling) with the 
list of publications cited by SignaLink. We found that in SignaLink the number of PubMed 
citations used per pathway is above the average of the listed databases. 
 
Listing cited papers 
For BioCarta we started from the URL http://www.biocarta.com/genes/allPathways.asp and 
downloaded the papers cited under “References” on the page of each pathway. From NetPath 
we downloaded and unzipped the file http://www.netpath.org/download/zipped/PSI-MI.zip 
and then listed pathways from this file. For KEGG we listed cited papers from the file 
ftp://ftp.genome.jp/pub/kegg/pathway/pathway. For the NCI database we started from the file  
http://pid.nci.nih.gov/browse_pathways.shtml and downloaded the references of all NCI-
curated pathways (subnetworks excluded). For pSTIING we started from the URL 
http://pstiing.licr.org/search/a_start_pathway.jsp, but could not locate the PubMed identifiers 
of the articles used for manual curation. For Reactome, we first downloaded the MySQL 
dump of the full database from http://www.reactome.org/download/index.html, but could not 
find the PubMed IDs in it. However, it was possible to download the list of PubMed IDs from 
the BioMart server at http://www.reactome.org/cgi-bin/mart. In the case of Science STKE 
(Signal Transduction Knowledge Environment) we started at the following URL: 
http://stke.sciencemag.org/cgi/collection, but could not find the list of PubMed IDs used for 
manual curation of the pathways. 
 
Final conclusions from the database comparisons 
It is widely assumed that so far in each investigated organism only a small portion of all 
protein-protein interactions – this includes signaling interactions – have been identified and 
most interactions remain to be mapped (Venkatesan et al, 2009). To minimise the number of 
false positives entered into SignaLink we have strictly adhered to the rules described above in 
the section titled “Manual curation process of SignaLink” during the curation process. Since 
the number of missing interactions is large in each signaling database and SignaLink was 
optimised towards minimizing the number of false positive interactions, we think that the high 
number of pathway proteins and the high number of interactions is one of the advantages of 
SignaLink. 
 
SignaLink was compiled based on reviews and primary research articles, therefore, the high 
numbers of proteins, cross-talks, and multi-pathway proteins indicate a high coverage (true 
positives). It is increasingly recognized that signaling pathways are not isolated entities, but 
form a single pathway system, thus, cross-talks and multi-pathway proteins are especially 
informative, and a high number of these entities (true positives) is also an advantage. As of 
yet only rough estimates can be made for the number of signaling interactions in the three 
investigated organisms, but the detailed description of the curation process of SignaLink 
provides strong support for its higher coverage. 
 
We note that Cusick et. al. (Cusick et al, 2009) have pointed out several drawbacks of 
manually curating “low-throughput” (LTP) data compared to collecting data with high-
throughput (HTP) methods. For the specific case of intracellular signaling we add the 
following comments to the results of Cusick et. al. In intracellular signaling (i) an 
exceptionally large portion of interactions is localised to, e.g., membranes, and cannot be 
efficiently detected with current HTP techniques, and (ii) the manual curation process of 
SignaLink eliminates some of the common disadvantageous features of manually curated 
databases (e.g., absence of proper documentation for the interactions) that have been 
highlighted by Cusick et.al. (2009). Most importantly, the manual curation process of 
SignaLink is based on a combination of experimental (research) and review articles. In the 
first set of sources (original research articles) experimental evidence is published, while in the 
second set of sources (review articles) specialists analyze available evidence about the 
relevance and quality of experimental data. 
 
Based on the comparisons between signaling databases, we found that compared to Reactome, 
NetPath, and KEGG the advantages of SignaLink are the following: 
• Precisely defined and documented curation protocol 
• Highest numbers of proteins and interactions for the curated signaling pathways 
• Highest numbers of cross-talks and multi-pathway proteins 
• Largest overlap with the other three databases 
• Number of publications per pathway higher than average 
• Minimal usage of isoforms  
• No binary interactions inferred from membership in the same protein complex 
• Low number of proteins for which there is not yet enough experimental evidence 
(these are proteins listed in UniProt/TrEMBL, not in UniProt/Swiss-Prot). 
 
Protein expression in healthy tissue types 
Selecting the expression data set: eGenetics  
Two of the currently available major, up-to-date sources of human tissue- (and organ-) 
specific protein expression data are the GNF Atlas (Su et al., 2004) and the eGenetics data set 
(Kelso et al., 2003). Both are integrated into Ensembl. The GNF Atlas was produced in a 
single series of experiments and it contains protein expression for 46 human tissues, organs, 
and cell lines. The eGenetics data set is a collection of small-scale experiments (7016 cDNA 
libraries represented in dbEST and 104 SAGE libraries) with protein expression data in a total 
of 50 different human tissue and organ types. In their top 19 tissue types the GNF Atlas and 
eGenetics contain protein expression for an average of 251.6 and 242.4 SignaLink proteins, 
respectively. In other words, the two expression data sets provide approximately the same 
coverage of SignaLink. We decided to use eGenetics because its data were more easily 
accessible. 
 
The eGenetics data set lists for each protein the tissue/organ types where that protein is 
expressed. This data set contains a total of 524 proteins from SignaLink. Out of these 323 are 
expressed in at least one tissue type (in the eGenetics ontology “anatomical system” means all 
tissue types). In Supplementary Table 10 we list the tissue and organ types where – according 
to eGenetics – the highest numbers of SignaLink proteins are expressed. This is the full list of 
tissue/organ types used in eGenetics (in alphabetical order): adrenal gland, alimentary, artery, 
auditory apparatus, basal nuclei, brain, brain stem, breast, cardiovascular, central nervous 
system, cerebellum, cerebral cortex, cerebrum, colorectal, dermal, diencephalon, endocrine, 
endocrine pancreas, epithalamus, female genitals, ganglion, haematological, heart, intestine, 
joint, liver and biliary system, lung, lymph node, lymphoreticular, male genitals, meninges, 
mesoderm, midbrain, muscle, musculoskeletal, omentum, oral cavity, osseous labyrinth, 
penis, peripheral nervous system, pharynx, respiratory, retina, skin, small intestine, 
subthalamus, urinary, urogenital, uterus, visual apparatus. 
 
 
eGenetics ontology Number of expressed 
SignaLink proteins  
Percent of human SignaLink proteins with 
pathway information present in eGenetics 
anatomical system (all tissue/organ types) 323 61.8% 
respiratory 303 57.9% 
male genitals 294 56.2% 
female genitals 293 56.0% 
central nervous system 288 55.1% 
Alimentary 264 50.5% 
Colorectal 261 49.9% 
Endocrine 249 47.6% 
Urinary 247 47.2% 
Dermal 246 47.0% 
visual apparatus 238 45.5% 
Musculoskeletal 237 45.3% 
liver and biliary system 236 45.1% 
Lymphoreticular 235 44.9% 
Cardiovascular 230 44.0% 
Uterus 220 42.1% 
Haematological 212 40.5% 
peripheral nervous system 190 36.3% 
Muscle 188 36.0% 
Breast 174 33.2% 
Supplementary Table 10. The number of expressed signaling proteins (from SignaLink) in each human 
tissue/organ type according to eGenetics. The five tissue types selected for the analyzes are marked with dark 
background color. 
 Selecting the five tissue types 
Our goal was to check whether human cross-talks are selectively active, i.e., whether cross-
talks connecting different pathway pairs are active in different numbers of tissue types. To 
obtain a statistically reliable statement, we decided to analyze several tissue types together. 
On the other hand, using expression from all tissue types together would blur the cross-talk 
differences we would like to detect. As an optimum we selected five tissue types. We listed 
from the full eGenetics expression data set only protein expression in these five tissues and 
merged this reduced expression data set with SignaLink. The criteria for selecting the five 
tissue types were the following: (i) eGenetics should contain expression data for a high 
number of SignaLink proteins in these five tissues, i.e., in eGenetics these five tissues should 
be as specific for SignaLink proteins as possible; (ii) each selected tissue type should be 
biologically homogeneous, and (iii) they should be of different origin (ecto-, meso-, 
entodermal) and function (e.g., skin, liver). 
 
To satisfy (i) we first listed the tissue types where the highest numbers of SignaLink proteins 
were expressed. Observe in Supplementary Table 10 that the first few tissue types on the list 
are rather heterogeneous: each of them is distributed among several organs, e.g., male and 
female genitals or the alimentary and endocrine systems. To satisfy conditions (ii) and (iii), 
we looked on this list for those five tissue types that were the most homogeneous and of 
sufficiently different origin. Thus, from the top of the list we selected cardiovascular, 
colorectal, and dermal tissues, the liver/biliary system, and muscle. Supplementary Table 11 
shows for each curated signaling pathway the portion of its proteins expressed in the five 
selected tissue types. 
 
 
 
 
Pathway Average expression of the pathway’s 
proteins in the five selected tissue types 
Notch 48.6% 
IGF 45.9% 
TGF 44.2% 
EGF/MAPK 42.3% 
NHR 38.8% 
Hh 34.2% 
WNT 33.3% 
JAK/STAT 25.8% 
Supplementary Table 11. Average percentage of the proteins of each human signaling pathway expressed in 
the five selected tissues types. For a given pathway we first computed the percent of its proteins expressed in 
each of the five selected tissue types and then we averaged this value over the five tissues. 
 
 
Supplementary Figure 4. Control for Figure 3a of the main text. See text for details. 
 
Controls 
 
For Figure 3a of the main text we applied two types of controls shown in Supplementary 
Figure 4. First, we performed separately for each of the five selected tissue types the same 
analysis as in Fig. 3a. Second, we selected the category “anatomical system” (i.e., all tissue 
types pooled). The main characteristics – discussed in the main text and in the supplementary 
material above – are preserved.  
 
 
Statistical significance analyses of pathway member protein functions 
Gene Ontology term enrichment tests in the curated signaling pathways  
For a rigorous statistical analysis of the functions of proteins in the curated pathways and their 
overlaps we performed statistical enrichment tests of Gene Ontology Biological Process terms 
using the hypergeometric distribution and a (Bonferroni) multiple hypothesis correction. We 
performed this test in each of the signaling pathways and their overlaps with the ‘GO 
Termfinder’ toolbox, implemented by (Boyle et al., 2004). Note that GO TermFinder uses a 
list of GO terms not only as a plain list, but it makes of the Directed Acyclic Graph (DAG) of 
GO terms to quantify the significance of term enrichment in a group of proteins. 
 
For each of the 22 signaling pathways available in SignaLink Supplementary Table 12 lists 
the 5 (for the EGF/MAPK pathway 6 or 7) most significant GO Biological Process terms. 
This analysis has pointed out that each pathway does have its own specific terms, many of 
which are explicitly are the GO terms named after the pathway, e.g., MAPKKK cascade. In 
each of the 3 species the listed (most significant) GO terms of different pathways are different 
terms, in other words: the listed pathways are functionally distinct entities. 
 
 
Caenorhabditis elegans 
 
Pathway in 
SignaLink 
Most significant GO Biological Process terms of the proteins of the pathway 
(with corrected P-values using a Bonferroni correction) 
EGF/MAPK GO:0040025 vulval development 7.3 * 10-31 
GO:0007165 signal transduction 2.1 * 10-28 
GO:0007154 cell communication 4.5 * 10-28 
GO:0040028 regulation of vulval development 1.2 * 10-23 
GO:0048580 regulation of post-embryonic development 1.2 * 10-23 
…   
GO:0000165 MAPKKK cascade 6.7 * 10-16 
…   
IGF GO:0040024 dauer larval development 4.7 * 10-16 
GO:0042221 response to chemical stimulus 2.6 * 10-14 
GO:0008286 insulin receptor signaling pathway 9.6 * 10-14 
GO:0032868 response to insulin stimulus 9.6 * 10-14 
GO:0032869 cellular response to insulin stimulus 9.6 * 10-14 
…   
NHR GO:0006350 transcription 0 (for all five GO terms) 
 
The SignaLink NHR 
pathway contains all 246 
C. elegans proteins in 
these 5 GO groups. 
GO:0006351 transcription, DNA-dependent 
GO:0006355 regulation of transcription, DNA-dependent 
GO:0009889 regulation of biosynthetic process 
GO:0010468 regulation of gene expression 
…   
NOTCH GO:0007219 Notch signaling pathway 1.1 * 10-19 
GO:0008593 regulation of Notch signaling pathway 2.4 * 10-12 
GO:0001708 cell fate specification 2.2 * 10-11 
GO:0045165 cell fate commitment 1.6 * 10-10 
GO:0045747 positive regulation of Notch signaling pathway 2.0 * 10-8 
…   
TGF GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway 6.4 * 10
-15 
GO:0007179 transforming growth factor beta receptor signaling pathway 3.3 * 10
-12 
GO:0007167 enzyme linked receptor protein signaling pathway 7.6 * 10-12 
GO:0040024 dauer larval development 2.0 * 10-11 
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 1.9 * 10
-10 
…   
WNT GO:0045165 cell fate commitment 3.2 * 10-37 
GO:0030154 cell differentiation 1.2 * 10-31 
GO:0048869 cellular developmental process 7.7 * 10-31 
GO:0001708 cell fate specification 2.5 * 10-28 
GO:0050794 regulation of cellular process 5.8 * 10-25 
…   
Supplementary Table 12a. The statistically most significant GO Biological Process terms for each signaling 
pathway of C. elegans curated in SignaLink. See the text above for details. 
 
 
Drosophila melanogaster 
 
Pathway in 
SignaLink 
Most significant GO Biological Process terms of the proteins of the pathway 
(with corrected P-values using a Bonferroni correction) 
EGF/MAPK GO:0007165 signal transduction 3.9 * 10-39 
GO:0007154 cell communication 1.1 * 10-35 
GO:0050794 regulation of cellular process 8.7 * 10-34 
GO:0050789 regulation of biological process 9.2 * 10-33 
GO:0007167 enzyme linked receptor protein signaling pathway 5.1 * 10-32 
…   
GO:0000165 MAPKKK cascade 4.9 * 10-24 
GO:0007173 epidermal growth factor receptor signaling pathway 6.5 * 10
-24 
…   
HH GO:0007224 smoothened signaling pathway 1.2 * 10-47 
GO:0008589 regulation of smoothened signaling pathway 1.2 * 10-29 
GO:0007166 cell surface receptor linked signal transduction 5.6 * 10-27 
GO:0007165 signal transduction 9.0 * 10-23 
GO:0007154 cell communication 1.1 * 10-20 
…   
IGF GO:0008286 insulin receptor signaling pathway 4.5 * 10-36 
GO:0032868 response to insulin stimulus 4.5 * 10-36 
GO:0032869 cellular response to insulin stimulus 4.5 * 10-36 
GO:0043434 response to peptide hormone stimulus 4.5 * 10-36 
GO:0032870 cellular response to hormone stimulus 8.3 * 10-34 
…   
JAK-STAT GO:0007259 JAK-STAT cascade 8.1 * 10-26 
GO:0007243 protein kinase cascade 2.2 * 10-18 
GO:0046425 regulation of JAK-STAT cascade 1.2 * 10-16 
GO:0007242 intracellular signaling cascade 2.4 * 10-12 
GO:0010627 regulation of protein kinase cascade 3.3 * 10-9 
…   
NHR GO:0006355 regulation of transcription, DNA-dependent 2.9 * 10-20 
GO:0051252 regulation of RNA metabolic process 1.5 * 10-19 
GO:0006351 transcription, DNA-dependent 2.2 * 10-19 
GO:0032774 RNA biosynthetic process 2.3 * 10-19 
GO:0045449 regulation of transcription 6.9 * 10-19 
…   
NOTCH GO:0007219 Notch signaling pathway 2.5 * 10-43 
GO:0007166 cell surface receptor linked signal transduction 1.8 * 10-26 
GO:0007154 cell communication 3.6 * 10-25 
GO:0007165 signal transduction 2.2 * 10-24 
GO:0008593 regulation of Notch signaling pathway 2.2 * 10-19 
…   
TGF GO:0007179 transforming growth factor beta receptor signaling pathway 1.5 * 10
-30 
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway 2.6 * 10
-28 
GO:0007167 enzyme linked receptor protein signaling pathway 1.1 * 10-19 
GO:0007165 signal transduction 2.4 * 10-18 
GO:0007166 cell surface receptor linked signal transduction 2.8 * 10-17 
…   
WNT GO:0016055 Wnt receptor signaling pathway 8.8 * 10-54 
GO:0007166 cell surface receptor linked signal transduction 1.7 * 10-34 
GO:0007165 signal transduction 4.6 * 10-27 
GO:0030111 regulation of Wnt receptor signaling pathway 5.6 * 10-25 
GO:0007154 cell communication 1.2 * 10-24 
…   
Supplementary Table 12b. The statistically most significant GO Biological Process terms for each signaling 
pathway of D. melanogaster curated in SignaLink. See the text above for details. 
 
 
Homo sapiens 
 
Pathway in 
SignaLink 
Most significant GO Biological Process terms of the proteins of the pathway 
(with corrected P-values using a Bonferroni correction) 
EGF/MAPK GO:0007243 protein kinase cascade 5.8 * 10-88 
GO:0006793 phosphorus metabolic process 1.8 * 10-80 
GO:0006796 phosphate metabolic process 1.8 * 10-87 
GO:0007242 intracellular signaling cascade 1.0 * 10-85 
GO:0016310 phosphorylation 1.8 * 10-83 
…   
GO:0000165 MAPKKK cascade 4.8 * 10-76 
…   
HH GO:0007224 smoothened signaling pathway 1.4 * 10-15 
GO:0009953 dorsal/ventral pattern formation 2.1 * 10-13 
GO:0007275 multicellular organismal development 4.9 * 10-13 
GO:0032502 developmental process 1.1 * 10-11 
GO:0048856 anatomical structure development 5.5 * 10-11 
…   
IGF GO:0032870 cellular response to hormone stimulus 1.7 * 10-26 
GO:0008286 insulin receptor signaling pathway 3.0 * 10-25 
GO:0032869 cellular response to insulin stimulus 1.2 * 10-24 
GO:0032868 response to insulin stimulus 1.6 * 10-24 
GO:0043434 response to peptide hormone stimulus 8.2 * 10-24 
…   
JAK-STAT GO:0007259 JAK-STAT cascade 1.3 * 10-60 
GO:0018108 peptidyl-tyrosine phosphorylation 5.7 * 10-48 
GO:0018212 peptidyl-tyrosine modification 1.2 * 10-47 
GO:0007243 protein kinase cascade 1.2 * 10-44 
GO:0007260 tyrosine phosphorylation of STAT protein 2.0 * 10-41 
…   
NHR GO:0006355 regulation of transcription, DNA-dependent 5.3 * 10-49 
GO:0051252 regulation of RNA metabolic process 1.7 * 10-48 
GO:0006351 transcription, DNA-dependent 1.6 * 10-47 
GO:0032774 RNA biosynthetic process 1.7 * 10-47 
GO:0016070 RNA metabolic process 2.1 * 10-41 
…   
NOTCH GO:0007219 Notch signaling pathway 3.2 * 10-49 
GO:0007166 cell surface receptor linked signal transduction 7.5 * 10-15 
GO:0032502 developmental process 4.1 * 10-12 
GO:0031293 membrane protein intracellular domain proteolysis 4.8 * 10
-12 
GO:0007389 pattern specification process 5.9 * 10-12 
…   
TGF GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway 3.4 * 10
-54 
GO:0007179 transforming growth factor beta receptor signaling pathway 4.1 * 10
-41 
GO:0007167 enzyme linked receptor protein signaling pathway 3.2 * 10-39 
GO:0043687 post-translational protein modification 1.2 * 10-35 
GO:0006464 protein modification process 5.5 * 10-33 
…   
WNT GO:0016055 Wnt receptor signaling pathway 1.8 * 10-88 
GO:0007166 cell surface receptor linked signal transduction 6.8 * 10-45 
GO:0007165 signal transduction 3.7 * 10-33 
GO:0007154 cell communication 1.0 * 10-30 
GO:0050794 regulation of cellular process 3.0 * 10-25 
…   
Supplementary Table 12c. The statistically most significant GO Biological Process terms for each human 
signaling pathway of curated in SignaLink. See the text above for details. 
 
Gene Ontology term similarity of human multi-pathway proteins and their pathways 
As explained above, we have computed with GO TermFinder the corrected P-values for the 
list of significantly enriched Gene Ontology terms in each signaling pathway. To estimate the 
significance with which a protein belongs to a pathway a natural first step is to find GO terms 
that annotate both the protein and the pathway. Here we quantify the significance with which 
an arbitrary protein belongs to an arbitrary signaling pathway as the smallest (most 
significant) P-value of a GO term of the pathway that annotates the selected protein too. 
 
In Supplementary Figure 5 we plot the results of three comparisons. First, we compute the 
above defined similarity for each human protein – SignaLink pathway pair, and plot the 
distribution of similarity scores. This is the control set shown in gray color in the figure. Next, 
we restrict the same comparison to protein-pathway pairs where the protein is a member of 
that pathway in SignaLink (red in the figure). Third, we restrict this comparison even further 
and use only such protein-pathway pairs, where the protein is a member of that pathway and it 
is a member of at least one other pathway, too, i.e., it is a multi-pathway protein (see blue 
boxes in the figure). We found that the similarity between multi-pathway proteins and their 
pathways has a peak at low P-values (high significance). The same holds for the comparisons 
between all pathway member protein and their pathways. On the other hand, in the control 
case (all proteins compared to all pathways) the peak of the distribution of similarities is at 
high P-values (low significance). 
 
 
 
Supplementary Figure 5. Distribution of the similarity scores between the functions (GO Biological Process) of 
a protein and the functions of a SignaLink pathway. For each of the 8 human signaling pathways curated in 
SignaLink, GO TermFinder was used to compute the P-values of GO Biological Process terms. Given a set of 
proteins, their GO terms (in one of three aspects: Biological Process, Cellular component, or Molecular 
Function) and the DAG (Directed Acyclic Graph) formatted hierarchy of these GO terms, GO TermFinder 
computes the P-value of each term for the group of proteins as a whole. A summary of this analysis is shown in 
Supplementary Table 12. See also the text above for details. Here we found that those pathway member proteins 
that belong to more than one pathway are significantly more similar to their pathways than the proteins in the 
control case (all proteins compared to all pathways). However, they are less similar to their pathways than those 
proteins that belong to one pathway only, most likely because they have multiple functions. See text for further 
details. 
 
Validation of the human interactions of SignaLink with an external resource 
We have evaluated the human interactions listed in SignaLink with the PRINCESS web 
service (Protein Interaction Confidence Evaluation System with Multiple Data Sources) (Li et 
al., 2008). Although PRINCESS can evaluate only human interactions, the majority of the 
interactions in SignaLink are human (991 from the total 1461), therefore, this analysis can 
provide representative information about the percent of true positive interactions in 
SignaLink. PRINCESS uses 7 different sources of interactions: (1) PPI databases; (2) Known 
interolog interactions; (3) Possibility for domain interaction; (4) GO_co-annotation; (5) 
Genome_context; (6) Gene_co-expression; (7) Network_topology information. 
 
From the 991 human protein-protein interactions listed in SignaLink, the PRINCESS web 
service recognized 982 interactions and from these 890 interactions received a likelihood 
score above the cutoff threshold for reliable interactions. Thus, according to this validation 
test the ratio of high confidence interactions among the human signaling interactions listed in 
SignaLink is 90.6%. (For detailed statistics see Supplementary Table 13.) The interactions for 
C. elegans and D. melanogaster were compiled with the same curation rules as for human, 
therefore, we expect similar ratios of true positive interactions in these two species too. 
 
 Number of interactions 
Interactions tested* 
(SignaLink human) 982 
High-confidence interactions** 890 
  
Source of evidence for high-
confidence interactions  
PPI_Database 201 
Interolog 13 
Interacting_Domain 810 
GO_Co-annotation 754 
Genome_Context 25 
Gene_Co-expression 117 
Network_Topology 451 
 
Supplementary Table 13. Statistics of the evaluation of human interactions listed in SignaLink with the 
PRINCESS web service. *From the 991 human interactions listed in SignaLink, PRINCESS recognized 982 
interactions. **Interactions with a likelihood ratio above 2.  
 
Database updates 
The next update of the SignaLink database is scheduled for the period January, 2011 – June, 
2011. 
 
Data sources and methods:  
• PubMed search for review papers of the curated signaling pathways. 
• Semi-automatic filtering of the PubMed abstracts returned after a search for the 
current member proteins of SignaLink pathways. 
• Publications listed (by PubMed ID) in the updates of major signaling databases. 
• Search for recent high-confident high-throughput databases on protein-protein 
interactions of signaling proteins. 
 
Participants:  
• T. Korcsmaros, I. J. Farkas, T. Vellai, and P. Csermely: improving curation guidelines. 
• T. Korcsmaros and D. Fazekas: curation. 
• I. J. Farkas and D. Fazekas: programming. 
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